/usr/local/Cellar/python3/3.6.1/Frameworks/Python.framework/Versions/3.6/bin/python3.6 /Users/emperor/HU/BA/semisuper/semisuper/tests/test_preproc.py
Loaded summaries and abstracts from disk.
No. of PubMed IDs:	 2344
No. of abstracts:	 1236
p<=1 P>6 	 [['p', '_ineq_', 'p', '_num_']]
5-year-old y.o. 	 [['_age_', '_age_']]
~1-2 23:24 	 [['_range_', '_ratio_']]
a>=b f=1 	 [['a', '_ineq_', '_ineq_']]
2-fold ~1-fold 	 [['_n_fold_', '_n_fold_']]
1:10 2-3 	 [['_ratio_', '_range_']]
12.2% % 1% 	 [['_num_', '_percent_', '_percent_', '_num_', '_percent_']]
1kg g mmol 2.2nm 	 [['_unit_', 'g', '_unit_', '_num_', '_unit_']]
rs2 rs333-wow 	 [['_gene_', '_mutation_', 'wow']]
jan March february 	 [['jan', 'march', 'february']]
1988 2001 20021 	 [['_year_', '_year_', '_num_']]
Zeroth first 2nd 22nd 23-th 9th 	 [['_num_', '_num_', '_num_', '_num_', '_num_', '_num_']]
-1.0 .99 ~2 	 [['_num_', '_num_', '_num_']]
V.S. vS Versus I.E. ie. E.g. iv. Po p.o. 	 [['vs', 'vs', 'vs', '_disease_', 'ie', 'eg', 'iv', 'po', 'po']]

---------------------------------------------------------------- 
Some tests. 
----------------------------------------------------------------

["He is going to be there, ie Dougie is going to be there.I can not wait to see how he's RS.123 doing.", 'conf fig 13 for additional information.', 'E.g.if you want to know the time, you should take b. Beispieltext ist schön.', 'first.', '10. we are going to cowabunga.', 'let there be rainbows.']
Janus kinase 2 JAK2 tyrosine kinase [['janus', 'kinase', '_num_', '_gene_', 'tyrosine', 'kinase']]
CLINICALTRIALSGOV: NCT00818441. [['clinicaltrialsgov', '_abbrev_']]
clinicaltrials.gov [['clinicaltrials', '_gene_']]
genetic/mrna [['genetic', 'mrna']]
C-->A G-->T [['c', 'a', 'g', 't']]
don't go wasting your emotions [['do', "n't", 'go', 'wasting', 'your', 'emotions']]
Eight inpatient rehabilitation facilities. [['_num_', 'inpatient', 'rehabilitation', 'facilities']]
There were 67 burst fractures, 48 compression fractures and 21 fracture dislocations, 8 flexion distraction fractures and 6 flexion rotation injuries. [['there', 'were', '_num_', 'burst', 'fractures', '_num_', 'compression', 'fractures', 'and', '_num_', 'fracture', 'dislocations', '_num_', 'flexion', 'distraction', 'fractures', 'and', '_num_', 'flexion', 'rotation', 'injuries']]
MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%). [['met', 'amplification', 'was', 'seen', 'in', '_num_', 'of', '_num_', '_num_', '_percent_', '_num_', '_percent_', 'ci', '_num_', '_percent_', '_num_', '_percent_']]
 [['_empty_sentence_']]

Shortest sentences

CIViC:

(IC50 = 110nm) 	 [['_abbrev_', '_ineq_', '_unit_']]
(family VHL 57). 	 [['family', '_gene_', '_num_']]
3 with SD, 1 with PD. 	 [['_num_', 'with', 'sd', '_num_', 'with', 'pd']]
ACMG codes as follows. 	 [['acmg', 'codes', 'as', 'follows']]
Her 10 month CEA was 1.4. 	 [['her', '_num_', 'month', '_gene_', 'was', '_num_']]
61,8% had a VHL mutation. 	 [['_num_', '_percent_', 'had', 'a', '_gene_', 'mutation']]
663 patients were tested. 	 [['_num_', 'patients', 'were', 'tested']]
This was called variant 5. 	 [['this', 'was', 'called', 'variant', '_num_']]
991 patients were enrolled. 	 [['_num_', 'patients', 'were', 'enrolled']]
No further testing was done. 	 [['no', 'further', 'testing', 'was', 'done']]
182 patients were evaluated. 	 [['_num_', 'patients', 'were', 'evaluated']]
HPO terms: hemangioblastoma. 	 [['_gene_', 'terms', '_disease_']]
Clinical trials are ongoing. 	 [['clinical', 'trials', 'are', 'ongoing']]
One had renal cell carcinoma. 	 [['_num_', 'had', 'renal', 'cell', 'carcinoma']]
One identified with angiomas. 	 [['_num_', 'identified', 'with', 'angiomas']]
Two had renal cell carcinoma. 	 [['_num_', 'had', 'renal', 'cell', 'carcinoma']]
Median OS was 29.9m vs. 25.9m. 	 [['median', 'os', 'was', '_num_', '_unit_', 'vs', '_num_', '_unit_']]
Overall, 5 patients had an OR. 	 [['overall', '_num_', 'patients', 'had', 'an', 'or']]
There was 1 complete response. 	 [['there', 'was', '_num_', 'complete', 'response']]
Mutation detected in one case. 	 [['mutation', 'detected', 'in', '_num_', 'case']]

Abstracts:

J. 	 [['_empty_sentence_']]
AIM. 	 [['_empty_sentence_']]
AIM. 	 [['_empty_sentence_']]
AIM. 	 [['_empty_sentence_']]
AIM. 	 [['_empty_sentence_']]
AIM. 	 [['_empty_sentence_']]
AIM. 	 [['_empty_sentence_']]
AIM. 	 [['_empty_sentence_']]
AIM. 	 [['_empty_sentence_']]
AIM. 	 [['_empty_sentence_']]
Cell. 	 [['_empty_sentence_']]
AIMS. 	 [['_empty_sentence_']]
AIMS. 	 [['_empty_sentence_']]
AIMS. 	 [['_empty_sentence_']]
AIMS. 	 [['_empty_sentence_']]
AIMS. 	 [['_empty_sentence_']]
Amgen. 	 [['amgen']]
METHOD. 	 [['method']]
Pfizer. 	 [['pfizer']]
METHOD. 	 [['method']]

PIBOSO other:

4) 	 [['_empty_sentence_']]
8) 	 [['_empty_sentence_']]
1. 	 [['_empty_sentence_']]
2. 	 [['_empty_sentence_']]
3. 	 [['_empty_sentence_']]
4. 	 [['_empty_sentence_']]
5. 	 [['_empty_sentence_']]
AIM 	 [['_empty_sentence_']]
(1) 	 [['_empty_sentence_']]
AIM 	 [['_empty_sentence_']]
AIM 	 [['_empty_sentence_']]
(1) 	 [['_empty_sentence_']]
AIM 	 [['_empty_sentence_']]
AIM 	 [['_empty_sentence_']]
AIM 	 [['_empty_sentence_']]
AIM 	 [['_empty_sentence_']]
AIM 	 [['_empty_sentence_']]
AIM 	 [['_empty_sentence_']]
AIM 	 [['_empty_sentence_']]
AIM 	 [['_empty_sentence_']]

PIBOSO outcome:

There were 18 deaths. 	 [['there', 'were', '_num_', 'deaths']]
Two (2%) patients died. 	 [['_num_', '_num_', '_percent_', 'patients', 'died']]
Overall mortality was 4%. 	 [['overall', 'mortality', 'was', '_num_', '_percent_']]
Overall mortality was 4%. 	 [['overall', 'mortality', 'was', '_num_', '_percent_']]
There were three failures. 	 [['there', 'were', '_num_', 'failures']]
This effect is reversible. 	 [['this', 'effect', 'is', 'reversible']]
Complications were minimal. 	 [['complications', 'were', 'minimal']]
Co-morbidity was also high. 	 [['co', 'morbidity', 'was', 'also', 'high']]
Other effects are uncertain. 	 [['other', 'effects', 'are', 'uncertain']]
Hospital mortality was 5.7%. 	 [['hospital', 'mortality', 'was', '_num_', '_percent_']]
The response rate was 79.5%. 	 [['the', 'response', 'rate', 'was', '_num_', '_percent_']]
Induction is contraindicated. 	 [['induction', 'is', 'contraindicated']]
Survival at 2.5 years was 72%. 	 [['survival', 'at', '_num_', 'years', 'was', '_num_', '_percent_']]
Mean tolerated dose was 7.6 mg. 	 [['mean', 'tolerated', 'dose', 'was', '_num_', '_unit_']]
No complications were observed. 	 [['no', 'complications', 'were', 'observed']]
Restitutio ad integrum resulted. 	 [['restitutio', 'ad', 'integrum', 'resulted']]
Two clinical trials are ongoing. 	 [['_num_', 'clinical', 'trials', 'are', 'ongoing']]
The average pain score was 1.28. 	 [['the', 'average', 'pain', 'score', 'was', '_num_']]
No safety concerns were evident. 	 [['no', 'safety', 'concerns', 'were', 'evident']]
Device interrogation was normal. 	 [['device', 'interrogation', 'was', 'normal']]

Longest sentences

CIViC:

Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537S ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines. 	 [['using', 'an', 'estrogen', 'response', 'element', 'ere', '', '_gene_', 'reporter', 'system', 'co', 'transfected', 'with', '_num_', 'of', '_num_', '_gene_', 'mutants', 'the', '_abbrev_', 'ligand', 'binding', 'domain', 'mutation', 'was', 'shown', 'to', 'result', 'in', 'constitutive', 'activity', 'response', 'in', 'the', 'absence', 'of', '_chemical_', 'ligand', 'and', 'continued', 'responsiveness', 'inhibition', 'of', 'downstream', 'target', 'activation', 'to', '_chemical_', 'therapies', 'tamoxifen', 'or', '_chemical_', 'in', '_abbrev_', 'cell', 'lines']]
Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537N ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines. 	 [['using', 'an', 'estrogen', 'response', 'element', 'ere', '', '_gene_', 'reporter', 'system', 'co', 'transfected', 'with', '_num_', 'of', '_num_', '_gene_', 'mutants', 'the', '_abbrev_', 'ligand', 'binding', 'domain', 'mutation', 'was', 'shown', 'to', 'result', 'in', 'constitutive', 'activity', 'response', 'in', 'the', 'absence', 'of', '_chemical_', 'ligand', 'and', 'continued', 'responsiveness', 'inhibition', 'of', 'downstream', 'target', 'activation', 'to', '_chemical_', 'therapies', 'tamoxifen', 'or', '_chemical_', 'in', '_abbrev_', 'cell', 'lines']]
Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the L536Q ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines. 	 [['using', 'an', 'estrogen', 'response', 'element', 'ere', '', '_gene_', 'reporter', 'system', 'co', 'transfected', 'with', '_num_', 'of', '_num_', '_gene_', 'mutants', 'the', '_abbrev_', 'ligand', 'binding', 'domain', 'mutation', 'was', 'shown', 'to', 'result', 'in', 'constitutive', 'activity', 'response', 'in', 'the', 'absence', 'of', '_chemical_', 'ligand', 'and', 'continued', 'responsiveness', 'inhibition', 'of', 'downstream', 'target', 'activation', 'to', '_chemical_', 'therapies', 'tamoxifen', 'or', '_chemical_', 'in', '_abbrev_', 'cell', 'lines']]
Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the N538G ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines. 	 [['using', 'an', 'estrogen', 'response', 'element', 'ere', '', '_gene_', 'reporter', 'system', 'co', 'transfected', 'with', '_num_', 'of', '_num_', '_gene_', 'mutants', 'the', '_abbrev_', 'ligand', 'binding', 'domain', 'mutation', 'was', 'shown', 'to', 'result', 'in', 'constitutive', 'activity', 'response', 'in', 'the', 'absence', 'of', '_chemical_', 'ligand', 'and', 'continued', 'responsiveness', 'inhibition', 'of', 'downstream', 'target', 'activation', 'to', '_chemical_', 'therapies', 'tamoxifen', 'or', '_chemical_', 'in', '_abbrev_', 'cell', 'lines']]
Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537C ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines. 	 [['using', 'an', 'estrogen', 'response', 'element', 'ere', '', '_gene_', 'reporter', 'system', 'co', 'transfected', 'with', '_num_', 'of', '_num_', '_gene_', 'mutants', 'the', '_abbrev_', 'ligand', 'binding', 'domain', 'mutation', 'was', 'shown', 'to', 'result', 'in', 'constitutive', 'activity', 'response', 'in', 'the', 'absence', 'of', '_chemical_', 'ligand', 'and', 'continued', 'responsiveness', 'inhibition', 'of', 'downstream', 'target', 'activation', 'to', '_chemical_', 'therapies', 'tamoxifen', 'or', '_chemical_', 'in', '_abbrev_', 'cell', 'lines']]
Among patients that had UMUCS but not G719 or L861, the response rate to tyrosine kinase inhibitors erlotinib or gefitinib, progression free survival, and overall survival were 20%, 1.6 month and 11.1 months, which was similar for wild type EGFR (16.5%, 2.0 months and 10.4 months), which contrasted to higher response for more commonly occurring G719 and L861 mutations (53.3% and 60.0%, respectively). 	 [['among', 'patients', 'that', 'had', 'umucs', 'but', 'not', '_abbrev_', 'or', '_abbrev_', 'the', 'response', 'rate', 'to', 'tyrosine', 'kinase', 'inhibitors', '_chemical_', 'or', '_chemical_', 'progression', 'free', 'survival', 'and', 'overall', 'survival', 'were', '_num_', '_percent_', '_num_', 'month', 'and', '_num_', 'months', 'which', 'was', 'similar', 'for', 'wild', 'type', '_gene_', '_num_', '_percent_', '_num_', 'months', 'and', '_num_', 'months', 'which', 'contrasted', 'to', 'higher', 'response', 'for', 'more', 'commonly', 'occurring', '_abbrev_', 'and', '_abbrev_', 'mutations', '_num_', '_percent_', 'and', '_num_', '_percent_', 'respectively']]
Patients with p53 wild type (as defined by low expression and/or wild type tp53 gene) had a higher response rate to chemotherapy-based treatment (total major response [MR]: risk ratio [RR] = 1.09, 95 % CI = 1.03-1.16, P = .003; pathological MR: RR = 1.15, 95 % CI = 1.06-1.25, P = .001; total complete response [CR]: RR = 1.08, 95 % CI = 1.00-1.17, P = .040) in this meta-analysis (28 studies, 1497 cases). 	 [['patients', 'with', '_gene_', 'wild', 'type', 'as', 'defined', 'by', 'low', 'expression', 'and', 'or', 'wild', 'type', '_gene_', 'gene', 'had', 'a', 'higher', 'response', 'rate', 'to', 'chemotherapy', 'based', 'treatment', 'total', 'major', 'response', 'mr', 'risk', 'ratio', 'rr', '_ineq_', '_num_', '_num_', '_percent_', 'ci', '_ineq_', '_range_', 'p', '_ineq_', '_num_', 'pathological', 'mr', 'rr', '_ineq_', '_num_', '_num_', '_percent_', 'ci', '_ineq_', '_range_', 'p', '_ineq_', '_num_', 'total', 'complete', 'response', 'cr', 'rr', '_ineq_', '_num_', '_num_', '_percent_', 'ci', '_ineq_', '_range_', 'p', '_ineq_', '_num_', 'in', 'this', '_disease_', 'analysis', '_num_', 'studies', '_num_', 'cases']]
In a randomized phase 3 study, previously untreated advanced or metastatic BRAF V600 mutation-positive melanoma patients treated with combination vemurafenib and cobimetinib showed improved progression free survival (9.9 vs 6.2 months), increased rate of complete or partial response (68% vs 45%), and improved overall survival at 9 months ( 81% vs 73%) compared to the vemurafenib and placebo control group. 	 [['in', 'a', 'randomized', 'phase', '_num_', 'study', 'previously', 'untreated', 'advanced', 'or', 'metastatic', '_gene_', '_abbrev_', 'mutation', 'positive', 'melanoma', 'patients', 'treated', 'with', 'combination', '_chemical_', 'and', '_chemical_', 'showed', 'improved', 'progression', 'free', 'survival', '_num_', 'vs', '_num_', 'months', 'increased', 'rate', 'of', 'complete', 'or', 'partial', 'response', '_num_', '_percent_', 'vs', '_num_', '_percent_', 'and', 'improved', 'overall', 'survival', 'at', '_num_', 'months', '_num_', '_percent_', 'vs', '_num_', '_percent_', 'compared', 'to', 'the', '_chemical_', 'and', 'placebo', 'control', 'group']]
In-silico modelling suggested loss of negative feedback on kinase activity from this deletion.In-vitro expression of the MEK1 Q56_V60 deletion as well as the previously characterized MEK1 F53L mutation in 293H cells resulted in elevated levels of phosphorylated ERK and phosphorylated ribosomal protein S6 kinase as compared with wild type MEK1 as well as increased colony formation and tumor growth in-vivo. 	 [['in', 'silico', 'modelling', 'suggested', 'loss', 'of', 'negative', 'feedback', 'on', 'kinase', 'activity', 'from', 'this', 'deletion', 'in', 'vitro', 'expression', 'of', 'the', '_gene_', '_abbrev_', 'deletion', 'as', 'well', 'as', 'the', 'previously', 'characterized', '_gene_', '_abbrev_', 'mutation', 'in', '293h', 'cells', 'resulted', 'in', 'elevated', 'levels', 'of', 'phosphorylated', '_gene_', 'and', 'phosphorylated', 'ribosomal', 'protein', '_abbrev_', 'kinase', 'as', 'compared', 'with', 'wild', 'type', '_gene_', 'as', 'well', 'as', 'increased', 'colony', 'formation', 'and', 'tumor', 'growth', 'in', 'vivo']]
In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with BRAF V600E (n=14) mutation treated with FOLFOX4 plus cetuximab were associated with a decreased progression free survival (7.2mo vs. 9.7mo, HR:0.39, 95% CI:0.21-0.72, P=0.0017), and decreased overall survival (11.7mo vs. 28.5mo, HR:0.23, 95% CI:0.12-0.41, P<0.0001), as compared to patients with wildtype BRAF. 	 [['in', 'a', 'retrospective', 'study', 'of', '_num_', 'treatment', 'naive', 'metastatic', 'colorectal', 'cancer', 'patients', 'patients', 'with', '_gene_', '_abbrev_', '_gene_', 'mutation', 'treated', 'with', '_abbrev_', 'plus', '_chemical_', 'were', 'associated', 'with', 'a', 'decreased', 'progression', 'free', 'survival', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'hr:0', '_num_', '_num_', '_percent_', 'ci:0', '_num_', '_num_', '_num_', '_p_val_', 'and', 'decreased', 'overall', 'survival', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'hr:0', '_num_', '_num_', '_percent_', 'ci:0', '_num_', '_num_', '_num_', 'p', '_num_', 'as', 'compared', 'to', 'patients', 'with', 'wildtype', '_gene_']]
In 3 cohorts of HPV-negative head and neck squamous cell carcinoma patient samples evaluated with different methods [reverse phase protein array (N=68), mRNA expression array (N=97) or immunohistochemistry (N=114), respectively], increased expression of PD-L1 was also correlated with local failure following radiotherapy as compared to the PD-L1–low expression group (P = 0.01, 1.9 × 10−3, and 9 × 10−4, respectively). 	 [['in', '_num_', 'cohorts', 'of', 'hpv', 'negative', 'head', 'and', 'neck', '_disease_', 'cell', 'carcinoma', 'patient', 'samples', 'evaluated', 'with', 'different', 'methods', 'reverse', 'phase', 'protein', 'array', '_ineq_', 'mrna', 'expression', 'array', '_ineq_', 'or', 'immunohistochemistry', '_ineq_', 'respectively', 'increased', 'expression', 'of', '_gene_', 'was', 'also', 'correlated', 'with', 'local', 'failure', 'following', 'radiotherapy', 'as', 'compared', 'to', 'the', 'pd', 'l1–low', 'expression', 'group', 'p', '_ineq_', '_num_', '_num_', '×', '10−3', 'and', '_num_', '×', '10−4', 'respectively']]
302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). 	 [['_num_', 'patients', '_num_', 'with', 'progression', 'events', 'with', '_gene_', 'negative', 'metastatic', 'breast', 'cancer', 'and', 'with', 'a', 'confirmed', 'deleterious', 'or', 'suspected', 'deleterious', 'germline', '_gene_', 'mutation', '_num_', '_gene_', '_num_', '_gene_', 'had', 'significantly', 'improved', 'progression', 'free', 'survival', 'and', 'better', 'response', 'rate', 'to', '_chemical_', '_gene_', 'inhibitor', 'than', 'standard', 'therapy', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'hazard', 'ratio', '_num_', '_num_', '_percent_', 'ci', '_range_', 'in', 'this', 'randomized', 'phase', '_num_', 'trial', '_abbrev_']]
Patients with PIK3CA somatic mutations on aspirin treatment were associated with an improved response (cancer-specific survival : HR:0.18, 95%CI:0.06-0.61, P<0.001, multivariate analysis for cancer-related death) and an improved overall survival (HR:0.54, 95%CI:0.31-0.94, P=0.01, multivariate analysis for death from any cause) when compared to those patients with PIK3CA mutations that did not use aspirin after diagnosis. 	 [['patients', 'with', '_gene_', 'somatic', 'mutations', 'on', 'aspirin', 'treatment', 'were', 'associated', 'with', 'an', 'improved', 'response', '_disease_', 'survival', 'hr:0', '_num_', '_num_', '_percent_', 'ci:0', '_num_', '_num_', '_num_', 'p', '_num_', 'multivariate', 'analysis', 'for', '_disease_', 'death', 'and', 'an', 'improved', 'overall', 'survival', 'hr:0', '_num_', '_num_', '_percent_', 'ci:0', '_num_', '_num_', '_num_', '_p_val_', 'multivariate', 'analysis', 'for', 'death', 'from', 'any', 'cause', 'when', 'compared', 'to', 'those', 'patients', 'with', '_gene_', 'mutations', 'that', 'did', 'not', 'use', 'aspirin', 'after', 'diagnosis']]
In the randomized UK LRF CCL4 phase 3 trial comparing first-line treatment with chlorambucil, fludarabine, or fludarabine plus cyclophosphamide, univariate analysis of patients with NOTCH1 mutations (within amino acids 2405-2525, a 399bp region of the PEST domain) demonstrated poorer overall survival (54.8 vs 74.6 months, P=0.02) and progression free survival (22 vs 26.4 months, P=0.02) compared to patients with wild type NOTCH1. 	 [['in', 'the', 'randomized', 'uk', '_gene_', '_gene_', 'phase', '_num_', 'trial', 'comparing', '_num_', 'line', 'treatment', 'with', 'chlorambucil', '_chemical_', 'or', '_chemical_', 'plus', '_chemical_', 'univariate', 'analysis', 'of', 'patients', 'with', '_gene_', 'mutations', 'within', 'amino', 'acids', '_range_', 'a', '399bp', 'region', 'of', 'the', 'pest', 'domain', 'demonstrated', 'poorer', 'overall', 'survival', '_num_', 'vs', '_num_', 'months', '_p_val_', 'and', 'progression', 'free', 'survival', '_num_', 'vs', '_num_', 'months', '_p_val_', 'compared', 'to', 'patients', 'with', 'wild', 'type', '_gene_']]
The complete remission rate for patients with RUNX1 mutations was significantly lower (48.4% vs. 68.1%; p <0.0001), the refractory disease rate was significantly higher (40.6% 23.4%; p=0.03), the 5-year event free survival rate was significantly lower (9%, 24%; p<0.0001), the 5-year relapse free survival rate was significantly lower (22%, 36%; p=0.0007), and the 5-year overall survival rate was significantly lower (22%, 37%; p=0.0001). 	 [['the', 'complete', 'remission', 'rate', 'for', 'patients', 'with', '_gene_', 'mutations', 'was', 'significantly', 'lower', '_num_', '_percent_', 'vs', '_num_', '_percent_', 'p', '_num_', 'the', 'refractory', 'disease', 'rate', 'was', 'significantly', 'higher', '_num_', '_percent_', '_num_', '_percent_', '_p_val_', 'the', '_num_', 'year', 'event', 'free', 'survival', 'rate', 'was', 'significantly', 'lower', '_num_', '_percent_', '_num_', '_percent_', 'p', '_num_', 'the', '_num_', 'year', 'relapse', 'free', 'survival', 'rate', 'was', 'significantly', 'lower', '_num_', '_percent_', '_num_', '_percent_', '_p_val_', 'and', 'the', '_num_', 'year', 'overall', 'survival', 'rate', 'was', 'significantly', 'lower', '_num_', '_percent_', '_num_', '_percent_', '_p_val_']]
This missense mutation was found in a VHL type 2B family of 7 individuals (Family ID 4414 in publication).Two of seven individuals were identified with retinal hemangioblastomas, 3 with cereballar hemangioblastomas, one with renal cell carcinoma, and one with pheochromocytomas.Supporting evidence of pathogenicity because cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (ACMG code: PP1). 	 [['this', 'missense', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_chemical_', 'family', 'of', '_num_', 'individuals', 'family', 'id', '_num_', 'in', 'publication', '_num_', 'of', '_num_', 'individuals', 'were', 'identified', 'with', 'retinal', '_disease_', '_num_', 'with', 'cereballar', '_disease_', '_num_', 'with', 'renal', 'cell', 'carcinoma', 'and', '_num_', 'with', 'pheochromocytomas', 'supporting', 'evidence', 'of', 'pathogenicity', 'because', 'cosegregation', 'with', 'disease', 'in', 'multiple', 'affected', 'family', 'members', 'in', 'a', 'gene', 'definitively', 'known', 'to', 'cause', 'the', 'disease', 'acmg', 'code', '_gene_']]
In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild type KRAS and NRAS. 	 [['in', 'a', 'retrospective', 'study', 'of', '_num_', 'treatment', 'naive', 'metastatic', 'colorectal', 'cancer', 'patients', 'patients', 'with', 'ras', 'mutations', '_gene_', 'including', '_gene_', '_abbrev_', '_gene_', '_abbrev_', 'nras', '_abbrev_', 'and', 'nras', '_abbrev_', 'treated', 'with', '_abbrev_', 'plus', '_chemical_', 'were', 'associated', 'with', 'decreased', 'overall', 'survival', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'hr:0', '_num_', '_num_', '_percent_', 'ci:0', '_num_', '_num_', '_num_', '_p_val_', 'and', 'decreased', 'progression', 'free', 'survival', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'hr:0', '_num_', '_num_', '_percent_', 'ci:0', '_num_', '_num_', '_num_', '_p_val_', 'as', 'compared', 'to', 'patients', 'with', 'wild', 'type', '_gene_', 'and', 'nras']]
In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations and wildtype BRAF (n=10), including A146T (N=3), G15D (N=1), and V152M/NRAS V160A, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild type KRAS, NRAS and BRAF. 	 [['in', 'a', 'retrospective', 'study', 'of', '_num_', 'treatment', 'naive', 'metastatic', 'colorectal', 'cancer', 'patients', 'patients', 'with', 'ras', 'mutations', 'and', 'wildtype', '_gene_', '_gene_', 'including', '_abbrev_', '_ineq_', '_abbrev_', '_ineq_', 'and', '_abbrev_', 'nras', '_abbrev_', 'treated', 'with', '_abbrev_', 'plus', '_chemical_', 'were', 'associated', 'with', 'decreased', 'overall', 'survival', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'hr:0', '_num_', '_num_', '_percent_', 'ci:0', '_num_', '_num_', '_num_', '_p_val_', 'and', 'decreased', 'progression', 'free', 'survival', '_num_', '_unit_', 'vs', '_num_', '_unit_', 'hr:0', '_num_', '_num_', '_percent_', 'ci:0', '_num_', '_num_', '_num_', '_p_val_', 'as', 'compared', 'to', 'patients', 'with', 'wild', 'type', '_gene_', 'nras', 'and', '_gene_']]
In this retrospective biomarker analysis of the EXPERT-C trial, patients with TP53 wild type status had a statistically significant better progression free survival (PFS) (89.3% vs 65.0% at 5 years; hazard ratio [HR] = 0.23; 95% confidence interval [CI] = 0.07 to 0.78; two-sided P = .02 by Cox regression) and overall survival (OS) (92.7% vs 67.5% at 5 years; HR = 0.16; 95% CI = 0.04 to 0.70; two-sided P = .02 by Cox regression) when treated with Cetuximab + CAPOX (Capecitabine, Oxaliplatin) than in the control arm without Cetuximab. 	 [['in', 'this', 'retrospective', '_chemical_', 'analysis', 'of', 'the', 'expert', 'c', 'trial', 'patients', 'with', '_gene_', 'wild', 'type', 'status', 'had', 'a', 'statistically', 'significant', 'better', 'progression', 'free', 'survival', 'progression', 'free survival', '_num_', '_percent_', 'vs', '_num_', '_percent_', 'at', '_num_', 'years', 'hazard', 'ratio', 'hr', '_ineq_', '_num_', '_num_', '_percent_', 'confidence', 'interval', 'ci', '_ineq_', '_num_', 'to', '_num_', '_num_', 'sided', 'p', '_ineq_', '_num_', 'by', 'cox', 'regression', 'and', 'overall', 'survival', 'os', '_num_', '_percent_', 'vs', '_num_', '_percent_', 'at', '_num_', 'years', 'hr', '_ineq_', '_num_', '_num_', '_percent_', 'ci', '_ineq_', '_num_', 'to', '_num_', '_num_', 'sided', 'p', '_ineq_', '_num_', 'by', 'cox', 'regression', 'when', 'treated', 'with', '_chemical_', 'capox', '_chemical_', '_chemical_', 'than', 'in', 'the', 'control', 'arm', 'without', '_chemical_']]
Overexpression of HIF1A was associated with higher colorectal cancer-specific mortality in Kaplan-Meier analysis (log-rank test, P < 0.0001), univariate Cox regression (hazard ratio = 1.84; 95% confidence interval, 1.37 to 2.47; P < 0.0001) and multivariate analysis (adjusted hazard ratio = 1.72; 95% confidence interval, 1.26 to 2.36; P = 0.0007, adjusted for clinical and tumoral features: microsatellite instability, TP53 (p53), PTGS2 (cyclooxygenase-2), CpG island methylator phenotype, and KRAS, BRAF, PIK3CA, and LINE-1 methylation). 	 [['overexpression', 'of', '_gene_', 'was', 'associated', 'with', 'higher', 'colorectal', '_disease_', 'mortality', 'in', 'kaplan', 'meier', 'analysis', 'log', 'rank', 'test', 'p', '_num_', 'univariate', 'cox', 'regression', 'hazard', 'ratio', '_ineq_', '_num_', '_num_', '_percent_', 'confidence', 'interval', '_num_', 'to', '_num_', 'p', '_num_', 'and', 'multivariate', 'analysis', 'adjusted', 'hazard', 'ratio', '_ineq_', '_num_', '_num_', '_percent_', 'confidence', 'interval', '_num_', 'to', '_num_', 'p', '_ineq_', '_num_', 'adjusted', 'for', 'clinical', 'and', '_disease_', 'features', '_disease_', 'instability', '_gene_', '_gene_', '_gene_', '_abbrev_', 'cpg', 'island', 'methylator', 'phenotype', 'and', '_gene_', '_gene_', '_gene_', 'and', '_abbrev_', 'methylation']]

Abstracts:

Low MGMT mRNA expression was strongly predictive for prolonged time to progression, treatment response, and length of survival in univariate and multivariate models (p<0.0001); the degree of MGMT mRNA expression was highly correlated with the MGMT promoter methylation status (p<0.0001); however, discordant findings were seen in 12 glioblastoma patients: Patients with methylated tumors with high MGMT mRNA expression (N = 6) did significantly worse than those with low transcriptional activity (p<0.01). 	 [['low', '_gene_', 'mrna', 'expression', 'was', 'strongly', 'predictive', 'for', 'prolonged', 'time', 'to', 'progression', 'treatment', 'response', 'and', 'length', 'of', 'survival', 'in', 'univariate', 'and', 'multivariate', 'models', 'p', '_num_', 'the', 'degree', 'of', '_gene_', 'mrna', 'expression', 'was', 'highly', 'correlated', 'with', 'the', '_gene_', 'promoter', 'methylation', 'status', 'p', '_num_', 'however', 'discordant', 'findings', 'were', 'seen', 'in', '_num_', 'glioblastoma', 'patients', 'patients', 'with', 'methylated', 'tumors', 'with', 'high', '_gene_', 'mrna', 'expression', 'n', '_ineq_', '_num_', 'did', 'significantly', 'worse', 'than', 'those', 'with', 'low', 'transcriptional', 'activity', 'p', '_num_']]
Among 991 randomly assigned patients, median progression-free survival as assessed by independent review was 9.6 months with T-DM1 versus 6.4 months with lapatinib plus capecitabine (hazard ratio for progression or death from any cause, 0.65; 95% confidence interval [CI], 0.55 to 0.77; P<0.001), and median overall survival at the second interim analysis crossed the stopping boundary for efficacy (30.9 months vs. 25.1 months; hazard ratio for death from any cause, 0.68; 95% CI, 0.55 to 0.85; P<0.001). 	 [['among', '_num_', 'randomly', 'assigned', 'patients', 'median', 'progression', 'free', 'survival', 'as', 'assessed', 'by', 'independent', 'review', 'was', '_num_', 'months', 'with', '_abbrev_', 'vs', '_num_', 'months', 'with', '_chemical_', 'plus', '_chemical_', 'hazard', 'ratio', 'for', 'progression', 'or', 'death', 'from', 'any', 'cause', '_num_', '_num_', '_percent_', 'confidence', 'interval', 'ci', '_num_', 'to', '_num_', 'p', '_num_', 'and', 'median', 'overall', 'survival', 'at', 'the', '_num_', 'interim', 'analysis', 'crossed', 'the', 'stopping', 'boundary', 'for', 'efficacy', '_num_', 'months', 'vs', '_num_', 'months', 'hazard', 'ratio', 'for', 'death', 'from', 'any', 'cause', '_num_', '_num_', '_percent_', 'ci', '_num_', 'to', '_num_', 'p', '_num_']]
Of the two most common adverse events (diarrhoea and rash or acne), grade 3 events were more common in patients receiving a 50 mg starting dose (22 [22%] of 99 patients for diarrhoea and 28 [28%] of 99 patients for rash or acne) than they were in those receiving a 40 mg starting dose (two [7%] of 30 patients for both diarrhoea and rash or acne); possibly treatment-related serious adverse events were also less common in patients receiving a 40 mg starting dose (two of 30 patients vs 14 of 99 patients). 	 [['of', 'the', '_num_', 'most', 'common', 'adverse', 'events', 'diarrhoea', 'and', 'rash', 'or', 'acne', 'grade', '_num_', 'events', 'were', 'more', 'common', 'in', 'patients', 'receiving', 'a', '_num_', '_unit_', 'starting', 'dose', '_num_', '_num_', '_percent_', 'of', '_num_', 'patients', 'for', 'diarrhoea', 'and', '_num_', '_num_', '_percent_', 'of', '_num_', 'patients', 'for', 'rash', 'or', 'acne', 'than', 'they', 'were', 'in', 'those', 'receiving', 'a', '_num_', '_unit_', 'starting', 'dose', '_num_', '_num_', '_percent_', 'of', '_num_', 'patients', 'for', 'both', 'diarrhoea', 'and', 'rash', 'or', 'acne', 'possibly', 'treatment', 'related', 'serious', 'adverse', 'events', 'were', 'also', 'less', 'common', 'in', 'patients', 'receiving', 'a', '_num_', '_unit_', 'starting', 'dose', '_num_', 'of', '_num_', 'patients', 'vs', '_num_', 'of', '_num_', 'patients']]
Analysis of genomic data from TCGA demonstrated coamplification of CCNE1 and AKT2 Overexpression of Cyclin E1 and AKT isoforms, in addition to mutant TP53, imparted malignant characteristics in untransformed fallopian tube secretory cells, the dominant site of origin of HGSC.Conclusions: These findings suggest a specific dependency of CCNE1-amplified tumors for AKT activity, and point to a novel combination of dinaciclib and AKT inhibitors that may selectively target patients with CCNE1-amplified HGSC. 	 [['analysis', 'of', 'genomic', 'data', 'from', 'tcga', 'demonstrated', 'coamplification', 'of', '_gene_', 'and', '_gene_', 'overexpression', 'of', '_gene_', '_abbrev_', 'and', '_gene_', 'isoforms', 'in', 'addition', 'to', 'mutant', '_gene_', 'imparted', 'malignant', 'characteristics', 'in', 'untransformed', '_disease_', 'tube', 'secretory', 'cells', 'the', 'dominant', 'site', 'of', 'origin', 'of', 'hgsc', 'conclusions', 'these', 'findings', 'suggest', 'a', 'specific', 'dependency', 'of', '_gene_', 'amplified', 'tumors', 'for', '_gene_', 'activity', 'and', 'point', 'to', 'a', 'novel', 'combination', 'of', '_chemical_', 'and', '_gene_', 'inhibitors', 'that', 'may', 'selectively', 'target', 'patients', 'with', '_gene_', 'amplified', 'hgsc']]
We show that (i) ATM- and ATR-mutated cells are hypersensitive to temozolomide, (ii) O(6)-MeG triggers ATM and ATR activation, (iii) knockdown of ATM and ATR enhances cell kill in gliobalstoma and malignant melanoma cells with a stronger and significant effect in ATR knockdown cells, (iv) ATR, but not ATM, knockdown abolished phosphorylation of H2AX, CHK1, and CHK2 in glioma cells, and (v) temozolomide-induced cell death was more prominently enhanced by pharmacologic inhibition of CHK1 compared with CHK2. 	 [['we', 'show', 'that', 'i', 'atm', '', 'and', '_gene_', 'mutated', 'cells', 'are', 'hypersensitive', 'to', '_chemical_', 'ii', 'o', '_num_', '', 'meg', 'triggers', 'atm', 'and', '_gene_', 'activation', 'iii', 'knockdown', 'of', 'atm', 'and', '_gene_', 'enhances', 'cell', 'kill', 'in', 'gliobalstoma', 'and', 'malignant', 'melanoma', 'cells', 'with', 'a', 'stronger', 'and', 'significant', 'effect', 'in', '_gene_', 'knockdown', 'cells', 'iv', '_gene_', 'but', 'not', 'atm', 'knockdown', 'abolished', '_disease_', 'of', '_abbrev_', '_gene_', 'and', '_gene_', 'in', 'glioma', 'cells', 'and', 'v', '_chemical_', 'induced', 'cell', 'death', 'was', 'more', 'prominently', 'enhanced', 'by', 'pharmacologic', 'inhibition', 'of', '_gene_', 'compared', 'with', '_gene_']]
However, in preplanned analyses, overall survival was significantly longer for patients with del19-positive tumours in the afatinib group than in the chemotherapy group in both trials: in LUX-Lung 3, median overall survival was 33.3 months (95% CI 26.8-41.5) in the afatinib group versus 21.1 months (16.3-30.7) in the chemotherapy group (HR 0.54, 95% CI 0.36-0.79, p=0.0015); in LUX-Lung 6, it was 31.4 months (95% CI 24.2-35.3) versus 18.4 months (14.6-25.6), respectively (HR 0.64, 95% CI 0.44-0.94, p=0.023). 	 [['however', 'in', 'preplanned', 'analyses', 'overall', 'survival', 'was', 'significantly', 'longer', 'for', 'patients', 'with', '_mutation_', 'positive', 'tumours', 'in', 'the', '_chemical_', 'group', 'than', 'in', 'the', 'chemotherapy', 'group', 'in', 'both', 'trials', 'in', 'lux', 'lung', '_num_', 'median', 'overall', 'survival', 'was', '_num_', 'months', '_num_', '_percent_', 'ci', '_range_', 'in', 'the', '_chemical_', 'group', 'vs', '_num_', 'months', '_range_', 'in', 'the', 'chemotherapy', 'group', 'hr', '_num_', '_num_', '_percent_', 'ci', '_range_', '_p_val_', 'in', 'lux', 'lung', '_num_', 'it', 'was', '_num_', 'months', '_num_', '_percent_', 'ci', '_range_', 'vs', '_num_', 'months', '_range_', 'respectively', 'hr', '_num_', '_num_', '_percent_', 'ci', '_range_', '_p_val_']]
From December 2003 to August 2005, 572 patients who had colorectal cancer expressing immunohistochemically detectable EGFR and who had been previously treated with a fluoropyrimidine, irinotecan, and oxaliplatin or had contraindications to treatment with these drugs underwent randomization to an initial dose of 400 mg of cetuximab per square meter of body-surface area followed by a weekly infusion of 250 mg per square meter plus best supportive care (287 patients) or best supportive care alone (285 patients). 	 [['from', 'december', '_year_', 'to', 'august', '_year_', '_num_', 'patients', 'who', 'had', 'colorectal', 'cancer', 'expressing', 'immunohistochemically', 'detectable', '_gene_', 'and', 'who', 'had', 'been', 'previously', 'treated', 'with', 'a', 'fluoropyrimidine', '_chemical_', 'and', '_chemical_', 'or', 'had', 'contraindications', 'to', 'treatment', 'with', 'these', 'drugs', 'underwent', 'randomization', 'to', 'an', 'initial', 'dose', 'of', '_num_', '_unit_', 'of', '_chemical_', 'per', 'square', 'meter', 'of', 'body', 'surface', 'area', 'followed', 'by', 'a', 'weekly', 'infusion', 'of', '_num_', '_unit_', 'per', 'square', 'meter', 'plus', 'best', 'supportive', 'care', '_num_', 'patients', 'or', 'best', 'supportive', 'care', 'alone', '_num_', 'patients']]
Women with HER2-positive, locally advanced or metastatic breast cancer that had progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab were randomly assigned to receive either combination therapy (lapatinib at a dose of 1250 mg per day continuously plus capecitabine at a dose of 2000 mg per square meter of body-surface area on days 1 through 14 of a 21-day cycle) or monotherapy (capecitabine alone at a dose of 2500 mg per square meter on days 1 through 14 of a 21-day cycle). 	 [['women', 'with', '_gene_', 'positive', 'locally', 'advanced', 'or', 'metastatic', 'breast', 'cancer', 'that', 'had', 'progressed', 'after', 'treatment', 'with', 'regimens', 'that', 'included', 'an', '_chemical_', 'a', '_chemical_', 'and', '_chemical_', 'were', 'randomly', 'assigned', 'to', 'receive', 'either', 'combination', 'therapy', '_chemical_', 'at', 'a', 'dose', 'of', '_num_', '_unit_', 'per', 'day', 'continuously', 'plus', '_chemical_', 'at', 'a', 'dose', 'of', '_year_', '_unit_', 'per', 'square', 'meter', 'of', 'body', 'surface', 'area', 'on', 'days', '_num_', 'through', '_num_', 'of', 'a', '_num_', 'day', 'cycle', 'or', 'monotherapy', '_chemical_', 'alone', 'at', 'a', 'dose', 'of', '_num_', '_unit_', 'per', 'square', 'meter', 'on', 'days', '_num_', 'through', '_num_', 'of', 'a', '_num_', 'day', 'cycle']]
Considering the high prevalence of female genital tract neoplasms, non-specific nature of the initial symptoms, higher possibility of metastasis by the time of diagnosis, importance of differentiating metastatic Mullerian tumors or metastatic breast cancer in the female genital tract, especially in the ovary, and lack of diagnostic markers with high sensitivity and specificity, the purpose of the current study was to evaluate the utility of Paired box protein8 (PAX8) expression in Mullerian and non-Mullerian neoplasms. 	 [['considering', 'the', 'high', 'prevalence', 'of', 'female', 'genital', 'tract', 'neoplasms', 'non', 'specific', 'nature', 'of', 'the', 'initial', 'symptoms', 'higher', 'possibility', 'of', 'metastasis', 'by', 'the', 'time', 'of', 'diagnosis', 'importance', 'of', 'differentiating', 'metastatic', 'mullerian', 'tumors', 'or', 'metastatic', 'breast', 'cancer', 'in', 'the', 'female', 'genital', 'tract', 'especially', 'in', 'the', 'ovary', 'and', 'lack', 'of', 'diagnostic', 'markers', 'with', 'high', 'sensitivity', 'and', 'specificity', 'the', 'purpose', 'of', 'the', 'current', 'study', 'was', 'to', 'evaluate', 'the', 'utility', 'of', 'paired', 'box', '_abbrev_', '_gene_', 'expression', 'in', 'mullerian', 'and', 'non', 'mullerian', 'neoplasms']]
In patients without BRCA1/2 mutations (n = 66), exploratory analyses showed that a BRCA-like genomic instability signature (n = 32) discriminated responding and nonresponding tumors (mean homologous recombination deficiency-loss of heterozygosity/homologous recombination deficiency-large-scale state transitions [HRD-LOH/HRD-LST] scores were 12.68 and 5.11, respectively), whereas predefined analysis by p63/p73 expression status (n = 61), p53 and PIK3CA mutation status (n = 53), or PAM50 gene expression subtype (n = 55) did not. 	 [['in', 'patients', 'without', '_gene_', 'mutations', 'n', '_ineq_', '_num_', 'exploratory', 'analyses', 'showed', 'that', 'a', '_gene_', 'like', 'genomic', 'instability', 'signature', 'n', '_ineq_', '_num_', 'discriminated', 'responding', 'and', 'nonresponding', 'tumors', 'mean', 'homologous', 'recombination', '_disease_', 'of', 'heterozygosity', 'homologous', 'recombination', 'deficiency', 'large', 'scale', 'state', 'transitions', '_gene_', 'loh', '_gene_', 'lst', 'scores', 'were', '_num_', 'and', '_num_', 'respectively', 'whereas', 'predefined', 'analysis', 'by', '_gene_', '_gene_', 'expression', 'status', 'n', '_ineq_', '_num_', '_gene_', 'and', '_gene_', 'mutation', 'status', 'n', '_ineq_', '_num_', 'or', '_abbrev_', 'gene', 'expression', 'subtype', 'n', '_ineq_', '_num_', 'did', 'not']]
In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-positive advanced non-small-cell lung cancer, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles; maintenance pemetrexed was allowed. 	 [['in', 'this', 'randomized', 'international', '_disease_', 'phase', '_num_', 'trial', 'we', 'assigned', '_num_', 'patients', 'with', '_abbrev_', 'positive', 'advanced', 'non', 'small', 'cell', 'lung', 'cancer', 'who', 'had', 'disease', 'progression', 'after', '_num_', 'line', '_gene_', 'tki', 'therapy', 'in', 'a', '_ratio_', 'ratio', 'to', 'receive', 'either', 'oral', '_chemical_', 'at', 'a', 'dose', 'of', '_num_', '_unit_', 'once', 'daily', 'or', 'intravenous', '_chemical_', '_num_', '_unit_', 'per', 'square', 'meter', 'of', 'body', 'surface', 'area', 'plus', 'either', '_chemical_', 'target', 'area', 'under', 'the', 'curve', '_num_', '_abbrev_', 'or', '_disease_', '_num_', '_unit_', 'per', 'square', 'meter', 'every', '_num_', 'weeks', 'for', 'up', 'to', '_num_', 'cycles', 'maintenance', '_chemical_', 'was', 'allowed']]
This patient and another patient with EML4-ALK variant 3a/b initially responded sequentially to crizotinib and then alectinib, a next-generation ALK inhibitor, but developed acquired resistance to alectinib with the presence of a mutation in amino acid residue 1171 (I1171N and I1171S respectively) located in the hydrophobic regulatory spine (R-spine) of the ALK kinase in both the cases as identified by a comprehensive next-generation sequencing-based assay performed on biopsies of new liver metastases that developed during alectinib treatment. 	 [['this', 'patient', 'and', 'another', 'patient', 'with', '_abbrev_', '_gene_', 'variant', '3a', 'b', 'initially', 'responded', 'sequentially', 'to', '_chemical_', 'and', 'then', '_chemical_', 'a', 'next', 'generation', '_gene_', 'inhibitor', 'but', 'developed', 'acquired', 'resistance', 'to', '_chemical_', 'with', 'the', 'presence', 'of', 'a', 'mutation', 'in', 'amino', 'acid', 'residue', '_num_', '_abbrev_', 'and', '_abbrev_', 'respectively', 'located', 'in', 'the', 'hydrophobic', 'regulatory', 'spine', 'r', 'spine', 'of', 'the', '_gene_', 'kinase', 'in', 'both', 'the', 'cases', 'as', 'identified', 'by', 'a', 'comprehensive', 'next', 'generation', 'sequencing', 'based', 'assay', 'performed', 'on', 'biopsies', 'of', 'new', 'liver', 'metastases', 'that', 'developed', 'during', '_chemical_', 'treatment']]
Survival in 56 crizotinib-treated, ALK-positive patients was similar to that in 63 ALK-negative, EGFR-positive patients given EGFR TKI therapy (median overall survival not reached [95% CI 17 months to not reached] vs 24 months [15-34], 1-year overall survival 71% [95% CI 58-81] vs 74% [61-83], and 2-year overall survival 57% [40-71] vs 52% [38-65]; p=0.786), whereas survival in 36 crizotinib-naive, ALK-positive controls was similar to that in 253 wild type controls (median overall survival 20 months [95% CI 13-26] vs 15 months [13-17]; p=0.244). 	 [['survival', 'in', '_num_', '_chemical_', 'treated', '_gene_', 'positive', 'patients', 'was', 'similar', 'to', 'that', 'in', '_num_', '_gene_', 'negative', '_gene_', 'positive', 'patients', 'given', '_gene_', 'tki', 'therapy', 'median', 'overall', 'survival', 'not', 'reached', '_num_', '_percent_', 'ci', '_num_', 'months', 'to', 'not', 'reached', 'vs', '_num_', 'months', '_range_', '_num_', 'year', 'overall', 'survival', '_num_', '_percent_', '_num_', '_percent_', 'ci', '_range_', 'vs', '_num_', '_percent_', '_range_', 'and', '_num_', 'year', 'overall', 'survival', '_num_', '_percent_', '_range_', 'vs', '_num_', '_percent_', '_range_', '_p_val_', 'whereas', 'survival', 'in', '_num_', '_chemical_', 'naive', '_gene_', 'positive', 'controls', 'was', 'similar', 'to', 'that', 'in', '_num_', 'wild', 'type', 'controls', 'median', 'overall', 'survival', '_num_', 'months', '_num_', '_percent_', 'ci', '_range_', 'vs', '_num_', 'months', '_range_', '_p_val_']]
HIF1A overexpression was significantly associated with higher colorectal cancer-specific mortality in Kaplan-Meier analysis (log-rank test, P < 0.0001), univariate Cox regression (hazard ratio = 1.84; 95% confidence interval, 1.37 to 2.47; P < 0.0001) and multivariate analysis (adjusted hazard ratio = 1.72; 95% confidence interval, 1.26 to 2.36; P = 0.0007) that adjusted for clinical and tumoral features, including microsatellite instability, TP53 (p53), PTGS2 (cyclooxygenase-2), CpG island methylator phenotype, and KRAS, BRAF, PIK3CA, and LINE-1 methylation. 	 [['_gene_', 'overexpression', 'was', 'significantly', 'associated', 'with', 'higher', 'colorectal', '_disease_', 'mortality', 'in', 'kaplan', 'meier', 'analysis', 'log', 'rank', 'test', 'p', '_num_', 'univariate', 'cox', 'regression', 'hazard', 'ratio', '_ineq_', '_num_', '_num_', '_percent_', 'confidence', 'interval', '_num_', 'to', '_num_', 'p', '_num_', 'and', 'multivariate', 'analysis', 'adjusted', 'hazard', 'ratio', '_ineq_', '_num_', '_num_', '_percent_', 'confidence', 'interval', '_num_', 'to', '_num_', 'p', '_ineq_', '_num_', 'that', 'adjusted', 'for', 'clinical', 'and', '_disease_', 'features', 'including', '_disease_', 'instability', '_gene_', '_gene_', '_gene_', '_abbrev_', 'cpg', 'island', 'methylator', 'phenotype', 'and', '_gene_', '_gene_', '_gene_', 'and', '_abbrev_', 'methylation']]
Eligible patients (>/=18 years, left ventricular ejection fraction >/=50%, Eastern Cooperative Oncology Group performance status 0-2) with progressive HER2-positive advanced breast cancer who had received two or more HER2-directed regimens in the advanced setting, including trastuzumab and lapatinib, and previous taxane therapy in any setting, were randomly assigned (in a 2:1 ratio) to trastuzumab emtansine (3.6 mg/kg intravenously every 21 days) or physician's choice using a permuted block randomisation scheme by an interactive voice and web response system. 	 [['eligible', 'patients', '_ineq_', 'years', 'left', 'ventricular', 'ejection', 'fraction', '_ineq_', '_percent_', 'eastern', 'cooperative', 'oncology', 'group', 'performance', 'status', '_range_', 'with', 'progressive', '_gene_', 'positive', 'advanced', 'breast', 'cancer', 'who', 'had', 'received', '_num_', 'or', 'more', '_gene_', 'directed', 'regimens', 'in', 'the', 'advanced', 'setting', 'including', '_chemical_', 'and', '_chemical_', 'and', 'previous', '_chemical_', 'therapy', 'in', 'any', 'setting', 'were', 'randomly', 'assigned', 'in', 'a', '_ratio_', 'ratio', 'to', '_chemical_', '_chemical_', '_num_', '_disease_', 'intravenously', 'every', '_num_', 'days', 'or', 'physician', "'s", 'choice', 'using', 'a', 'permuted', 'block', 'randomisation', 'scheme', 'by', 'an', 'interactive', 'voice', 'and', 'web', 'response', 'system']]
Tumor recurrence rates were 25.8% (50 of 194;77.60 recurrences per 1,000 person-years; 95% CI, 58.81 to 102.38) versus 9.6% (30 of 313; 22.88 recurrences per 1,000 person-years; 95% CI, 16.00 to 32.72) in BRAF mutation-positive versus -negative patients (hazard ratio [HR], 3.22; 95% CI, 2.05 to 5.07) and 47.5% (29 of 61; 108.55 recurrences per 1,000 person-years; 95% CI, 75.43 to 156.20) versus 11.4% (51 of 446; 30.21 recurrences per 1,000 person-years; 95% CI, 22.96 to 39.74) in TERT mutation-positive versus -negative patients (HR, 3.46; 95% CI, 2.19 to 5.45). 	 [['tumor', 'recurrence', 'rates', 'were', '_num_', '_percent_', '_num_', 'of', '_num_', '_num_', 'recurrences', 'per', '_num_', '_disease_', '_num_', '_percent_', 'ci', '_num_', 'to', '_num_', 'vs', '_num_', '_percent_', '_num_', 'of', '_num_', '_num_', 'recurrences', 'per', '_num_', '_disease_', '_num_', '_percent_', 'ci', '_num_', 'to', '_num_', 'in', '_gene_', 'mutation', 'positive', 'vs', '', 'negative', 'patients', 'hazard', 'ratio', 'hr', '_num_', '_num_', '_percent_', 'ci', '_num_', 'to', '_num_', 'and', '_num_', '_percent_', '_num_', 'of', '_num_', '_num_', 'recurrences', 'per', '_num_', '_disease_', '_num_', '_percent_', 'ci', '_num_', 'to', '_num_', 'vs', '_num_', '_percent_', '_num_', 'of', '_num_', '_num_', 'recurrences', 'per', '_num_', '_disease_', '_num_', '_percent_', 'ci', '_num_', 'to', '_num_', 'in', '_gene_', 'mutation', 'positive', 'vs', '', 'negative', 'patients', 'hr', '_num_', '_num_', '_percent_', 'ci', '_num_', 'to', '_num_']]
Lower BAP1 gene expression and negative BAP1 immunostaining (50% of 28 tumours were immunonegative) were both associated with these markers for prognostication: FISH cut-off 30% monosomy 3 (BAP1 gene expression: p=0.037; BAP1 immunostaining: p=0.001), SNP-monosomy 3 (BAP1 gene expression: p=0.008; BAP1 immunostaining: p=0.002) and class 2 profile (BAP1 gene expression: p<0.001; BAP1 immunostaining: p=0.001) and were themselves associated with an increased risk of death due to metastasis (BAP1 gene expression dichotomised: HR 8.7, p=0.006; BAP1 immunostaining: HR 4.0, p=0.010). 	 [['lower', '_gene_', 'gene', 'expression', 'and', 'negative', '_gene_', 'immunostaining', '_num_', '_percent_', 'of', '_num_', 'tumours', 'were', 'immunonegative', 'were', 'both', 'associated', 'with', 'these', 'markers', 'for', 'prognostication', 'fish', 'cut', 'off', '_num_', '_percent_', 'monosomy', '_num_', '_gene_', 'gene', 'expression', '_p_val_', '_gene_', 'immunostaining', '_p_val_', 'snp', 'monosomy', '_num_', '_gene_', 'gene', 'expression', '_p_val_', '_gene_', 'immunostaining', '_p_val_', 'and', 'class', '_num_', 'profile', '_gene_', 'gene', 'expression', 'p', '_num_', '_gene_', 'immunostaining', '_p_val_', 'and', 'were', 'themselves', 'associated', 'with', 'an', 'increased', 'risk', 'of', 'death', 'due', 'to', 'metastasis', '_gene_', 'gene', 'expression', 'dichotomised', 'hr', '_num_', '_p_val_', '_gene_', 'immunostaining', 'hr', '_num_', '_p_val_']]
In the subgroup of 261 patients who were positive for the epidermal growth factor receptor gene (EGFR) mutation, progression-free survival was significantly longer among those who received gefitinib than among those who received carboplatin-paclitaxel (hazard ratio for progression or death, 0.48; 95% CI, 0.36 to 0.64; P<0.001), whereas in the subgroup of 176 patients who were negative for the mutation, progression-free survival was significantly longer among those who received carboplatin-paclitaxel (hazard ratio for progression or death with gefitinib, 2.85; 95% CI, 2.05 to 3.98; P<0.001). 	 [['in', 'the', 'subgroup', 'of', '_num_', 'patients', 'who', 'were', 'positive', 'for', 'the', 'epidermal', 'growth', 'factor', 'receptor', 'gene', '_gene_', 'mutation', 'progression', 'free', 'survival', 'was', 'significantly', 'longer', 'among', 'those', 'who', 'received', '_chemical_', 'than', 'among', 'those', 'who', 'received', '_chemical_', 'hazard', 'ratio', 'for', 'progression', 'or', 'death', '_num_', '_num_', '_percent_', 'ci', '_num_', 'to', '_num_', 'p', '_num_', 'whereas', 'in', 'the', 'subgroup', 'of', '_num_', 'patients', 'who', 'were', 'negative', 'for', 'the', 'mutation', 'progression', 'free', 'survival', 'was', 'significantly', 'longer', 'among', 'those', 'who', 'received', '_chemical_', 'hazard', 'ratio', 'for', 'progression', 'or', 'death', 'with', '_chemical_', '_num_', '_num_', '_percent_', 'ci', '_num_', 'to', '_num_', 'p', '_num_']]
Patients with WT1 mutations had an inferior response to induction chemotherapy compared with wild type cases (complete remission rate, 79% v 90%, odds ratio [OR] = 3.02; 95% CI, 1.17 to 7.82; P = .02), a higher rate of resistant disease (15% v 4%; OR = 9.33; 95% CI, 2.38 to 36.6; P = .001), an increased cumulative incidence of relapse (67% v 43%, hazard ratio [HR] = 3.02; 95% CI, 1.69 to 5.38; P = .0008), with a reduction in both relapse-free survival (22% v 44%; HR = 2.16; 95% CI, 1.32 to 3.55; P = .005) and overall survival (26% v 47%; HR = 1.91; 95% CI, 1.23 to 2.95; P = .007) at 5 years. 	 [['patients', 'with', '_gene_', 'mutations', 'had', 'an', 'inferior', 'response', 'to', 'induction', 'chemotherapy', 'compared', 'with', 'wild', 'type', 'cases', 'complete', 'remission', 'rate', '_num_', '_percent_', 'v', '_num_', '_percent_', 'odds', 'ratio', 'or', '_ineq_', '_num_', '_num_', '_percent_', 'ci', '_num_', 'to', '_num_', 'p', '_ineq_', '_num_', 'a', 'higher', 'rate', 'of', 'resistant', 'disease', '_num_', '_percent_', 'v', '_num_', '_percent_', 'or', '_ineq_', '_num_', '_num_', '_percent_', 'ci', '_num_', 'to', '_num_', 'p', '_ineq_', '_num_', 'an', 'increased', 'cumulative', 'incidence', 'of', 'relapse', '_num_', '_percent_', 'v', '_num_', '_percent_', 'hazard', 'ratio', 'hr', '_ineq_', '_num_', '_num_', '_percent_', 'ci', '_num_', 'to', '_num_', 'p', '_ineq_', '_num_', 'with', 'a', 'reduction', 'in', 'both', 'relapse', 'free', 'survival', '_num_', '_percent_', 'v', '_num_', '_percent_', 'hr', '_ineq_', '_num_', '_num_', '_percent_', 'ci', '_num_', 'to', '_num_', 'p', '_ineq_', '_num_', 'and', 'overall', 'survival', '_num_', '_percent_', 'v', '_num_', '_percent_', 'hr', '_ineq_', '_num_', '_num_', '_percent_', 'ci', '_num_', 'to', '_num_', 'p', '_ineq_', '_num_', 'at', '_num_', 'years']]
The goal of this study was to examine this phenomenon using an unbiased approach.Experimental Design: We utilized human papilloma virus (HPV)-negative cell lines rendered radiation-resistant (RR) via repeated exposure to radiation, a panel of HPV-negative HNSCC cell lines and three cohorts of HPV-negative HNSCC tumors (n = 68, 97, and 114) from patients treated with radiotherapy and subjected to genomic, transcriptomic, and proteomic analysis.Results: RR cell lines exhibited upregulation of several proteins compared with controls, including increased activation of Axl and PI3 kinase signaling as well as increased expression of PD-L1. 	 [['the', 'goal', 'of', 'this', 'study', 'was', 'to', 'examine', 'this', 'phenomenon', 'using', 'an', 'unbiased', 'approach', 'experimental', 'design', 'we', 'utilized', 'human', 'papilloma', 'virus', 'hpv', '', 'negative', 'cell', 'lines', 'rendered', 'radiation', 'resistant', 'rr', 'via', 'repeated', 'exposure', 'to', 'radiation', 'a', 'panel', 'of', 'hpv', 'negative', 'hnscc', 'cell', 'lines', 'and', '_num_', 'cohorts', 'of', 'hpv', 'negative', 'hnscc', 'tumors', 'n', '_ineq_', '_num_', '_num_', 'and', '_num_', 'from', 'patients', 'treated', 'with', 'radiotherapy', 'and', 'subjected', 'to', 'genomic', 'transcriptomic', 'and', 'proteomic', 'analysis', 'results', 'rr', 'cell', 'lines', 'exhibited', 'upregulation', 'of', 'several', 'proteins', 'compared', 'with', 'controls', 'including', 'increased', 'activation', 'of', '_gene_', 'and', '_gene_', 'kinase', 'signaling', 'as', 'well', 'as', 'increased', 'expression', 'of', '_gene_']]

PIBOSO other:

Distribution by country of corresponding author Jordan (9 RCTs, 2 CCTs), Bahrain (3 RCTs), Egypt (one RCT), Kuwait (one RCT), and Saudi Arabia (one RCT); and by specialty Anesthesia (7), General Surgery (3), Obstetrics/Gynecology (1), Radiotherapy (1), Pediatrics (1), Orthopaedic Surgery (1), Education (1) Ear Nose and Throat (1) Ophthalmology (1). 	 [['distribution', 'by', 'country', 'of', 'corresponding', 'author', 'jordan', '_num_', 'rcts', '_num_', 'ccts', 'bahrain', '_num_', 'rcts', 'egypt', '_num_', 'rct', 'kuwait', '_num_', 'rct', 'and', 'saudi', 'arabia', '_num_', 'rct', 'and', 'by', 'specialty', 'anesthesia', '_num_', 'general', 'surgery', '_num_', 'obstetrics', 'gynecology', '_num_', 'radiotherapy', '_num_', 'pediatrics', '_num_', 'orthopaedic', 'surgery', '_num_', 'education', '_num_', 'ear', 'nose', 'and', 'throat', '_num_', 'ophthalmology', '_num_']]
We searched for randomised controlled trials (RCTs) or quasi-randomised controlled trials including cluster randomised trials and controlled clinical trials (CCTs), and controlled before and after studies (CBAs), in which family-centred care models are compared with professionally-centred models of care for hospitalised children (aged up to 12 years). 	 [['we', 'searched', 'for', 'randomised', 'controlled', 'trials', 'rcts', 'or', 'quasi', 'randomised', 'controlled', 'trials', 'including', 'cluster', 'randomised', 'trials', 'and', 'controlled', 'clinical', 'trials', 'ccts', 'and', 'controlled', 'before', 'and', 'after', 'studies', 'cbas', 'in', 'which', 'family', 'centred', 'care', 'models', 'are', 'compared', 'with', 'professionally', 'centred', 'models', 'of', 'care', 'for', 'hospitalised', 'children', 'aged', 'up', 'to', '_num_', 'years']]
Areas of significant disagreement included the timing and indications for surgical intervention in birth-related palsy, treatment of neuroma-in-continuity, the best transfers to achieve elbow flexion and shoulder abduction, the use of intra- or extraplexal donors for motor neurotization, and the use of distal or proximal coaptation during nerve transfer. 	 [['areas', 'of', 'significant', 'disagreement', 'included', 'the', 'timing', 'and', 'indications', 'for', 'surgical', 'intervention', 'in', 'birth', 'related', 'palsy', 'treatment', 'of', 'neuroma', 'in', 'continuity', 'the', 'best', 'transfers', 'to', 'achieve', 'elbow', 'flexion', 'and', 'shoulder', 'abduction', 'the', 'use', 'of', 'intra', '', 'or', 'extraplexal', 'donors', 'for', 'motor', '_disease_', 'and', 'the', 'use', 'of', 'distal', 'or', 'proximal', 'coaptation', 'during', 'nerve', 'transfer']]
To assess the effectiveness and cost effectiveness of counselling in primary care by reviewing cost and outcome data in randomised controlled trials, controlled clinical trials and controlled patient preference trials of counselling interventions in primary care, for patients with psychological and psychosocial problems considered suitable for counselling. 	 [['to', 'assess', 'the', 'effectiveness', 'and', 'cost', 'effectiveness', 'of', 'counselling', 'in', 'primary', 'care', 'by', 'reviewing', 'cost', 'and', 'outcome', 'data', 'in', 'randomised', 'controlled', 'trials', 'controlled', 'clinical', 'trials', 'and', 'controlled', 'patient', 'preference', 'trials', 'of', 'counselling', 'interventions', 'in', 'primary', 'care', 'for', 'patients', 'with', 'psychological', 'and', '_disease_', 'problems', 'considered', 'suitable', 'for', 'counselling']]
Distribution by country of corresponding author Jordan (4 RCTs, one CCT), Bahrain (one RCT, one CCT), India (3 RCTs, one CCT), Kuwait (one CCT), Saudi Arabia (2 RCTs), USA/Bahrain (one RCT), and Oman (one RCT); and by specialty Anesthesia (8), Surgery (1) Pediatrics (1), Radiotherapy (1), Community Medicine (1), Sports Medicine (1), Obstetrics/Gynecology (3). 	 [['distribution', 'by', 'country', 'of', 'corresponding', 'author', 'jordan', '_num_', 'rcts', '_num_', '_gene_', 'bahrain', '_num_', 'rct', '_num_', '_gene_', 'india', '_num_', 'rcts', '_num_', '_gene_', 'kuwait', '_num_', '_gene_', 'saudi', 'arabia', '_num_', 'rcts', 'usa', 'bahrain', '_num_', 'rct', 'and', 'oman', '_num_', 'rct', 'and', 'by', 'specialty', 'anesthesia', '_num_', 'surgery', '_num_', 'pediatrics', '_num_', 'radiotherapy', '_num_', 'community', 'medicine', '_num_', 'sports', 'medicine', '_num_', 'obstetrics', 'gynecology', '_num_']]
Reliability was estimated using Cronbach's alpha and test-retest correlation coefficients, and validity was examined by comparing FIM-SR scores with the Craig Handicap Assessment and Reporting Technique (CHART) by comparing the CHART scores between the participants with SCI and amputation, and by comparing CHART scores between subjects with different levels of SCI. 	 [['reliability', 'was', 'estimated', 'using', 'cronbach', "'s", 'alpha', 'and', '_disease_', 'correlation', 'coefficients', 'and', 'validity', 'was', 'examined', 'by', 'comparing', '_gene_', 'sr', 'scores', 'with', 'the', 'craig', 'handicap', 'assessment', 'and', 'reporting', 'technique', 'chart', 'by', 'comparing', 'the', 'chart', 'scores', 'between', 'the', 'participants', 'with', 'sci', 'and', 'amputation', 'and', 'by', 'comparing', 'chart', 'scores', 'between', 'subjects', 'with', 'different', 'levels', 'of', 'sci']]
Efficacy will be assessed in terms of faster improvements in range of motion and functional recovery.Seventy patients with knee osteoarthritis undergoing TKA and experiencing early postoperative flexion impairment (less than 80 degrees of knee flexion at the time of discharge) will be randomised over two treatment groups, a usual care group and an experimental group. 	 [['efficacy', 'will', 'be', 'assessed', 'in', 'terms', 'of', 'faster', 'improvements', 'in', 'range', 'of', 'motion', 'and', 'functional', 'recovery', '_num_', 'patients', 'with', 'knee', 'osteoarthritis', 'undergoing', 'tka', 'and', 'experiencing', 'early', 'postoperative', 'flexion', 'impairment', 'less', 'than', '_num_', 'degrees', 'of', 'knee', 'flexion', 'at', 'the', 'time', 'of', 'discharge', 'will', 'be', 'randomised', 'over', '_num_', 'treatment', 'groups', 'a', 'usual', 'care', 'group', 'and', 'an', 'experimental', 'group']]
To determine the beneficial and harmful effects of different fixed recall intervals (for example 6 months versus 12 months) for the following different types of dental check-up a) clinical examination only; b) clinical examination plus scale and polish; c) clinical examination plus preventive advice; d) clinical examination plus preventive advice plus scale and polish. 	 [['to', 'determine', 'the', 'beneficial', 'and', 'harmful', 'effects', 'of', 'different', 'fixed', 'recall', 'intervals', 'for', 'example', '_num_', 'months', 'vs', '_num_', 'months', 'for', 'the', 'following', 'different', 'types', 'of', 'dental', 'check', 'up', 'a', 'clinical', 'examination', 'only', 'b', 'clinical', 'examination', 'plus', 'scale', 'and', 'polish', 'c', 'clinical', 'examination', 'plus', 'preventive', 'advice', 'd', 'clinical', 'examination', 'plus', 'preventive', 'advice', 'plus', 'scale', 'and', 'polish']]
Eligible trials were identified through searches of The Cochrane Hepato-Biliary Group Controlled Trials Register (August 2005), The Cochrane Central Register of Controlled Trials in The Cochrane Library (Issue 3, 2005), MEDLINE (1950 to August 2005), EMBASE (1980 to August 2005), Science Citation Index EXPANDED (1945 to August 2005), and reference lists of relevant articles. 	 [['eligible', 'trials', 'were', 'identified', 'through', 'searches', 'of', 'the', 'cochrane', '_disease_', 'group', 'controlled', 'trials', 'register', 'august', '_year_', 'the', 'cochrane', 'central', 'register', 'of', 'controlled', 'trials', 'in', 'the', 'cochrane', 'library', 'issue', '_num_', '_year_', 'medline', '_year_', 'to', 'august', '_year_', 'embase', '_year_', 'to', 'august', '_year_', 'science', 'citation', 'index', 'expanded', '_year_', 'to', 'august', '_year_', 'and', 'reference', 'lists', 'of', 'relevant', 'articles']]
The main outcome measured was change in 9 preventive services areas (1) immunizations up to date; (2) anemia screening; (3) tuberculosis risk assessment and indicated screening; (4) lead screening; (5) infant sleep position counseling; (6) environmental tobacco smoke-exposure risk assessment; (7) blood pressure screening; (8) vision screening; and (9) dental risk assessment. 	 [['the', 'main', 'outcome', 'measured', 'was', 'change', 'in', '_num_', 'preventive', 'services', 'areas', '_num_', 'immunizations', 'up', 'to', 'date', '_num_', 'anemia', 'screening', '_num_', 'tuberculosis', 'risk', 'assessment', 'and', 'indicated', 'screening', '_num_', 'lead', 'screening', '_num_', 'infant', 'sleep', 'position', 'counseling', '_num_', 'environmental', 'tobacco', 'smoke', 'exposure', 'risk', 'assessment', '_num_', 'blood', 'pressure', 'screening', '_num_', 'vision', 'screening', 'and', '_num_', 'dental', 'risk', 'assessment']]
A systematic search of Ovid, MEDLINE, psychINFO, PsycARTICLES, CINAHL, and EMBASE databases of papers published between 1993 and 2004 was conducted, using the following medical subject headings or key words insomnia, primary insomnia, psychophysiological insomnia, sleep maintenance disorders, sleep initiation disorders, non-pharmacological treatment, and cognitive behavioural therapy. 	 [['a', 'systematic', 'search', 'of', 'ovid', 'medline', 'psychinfo', 'psycarticles', 'cinahl', 'and', 'embase', 'databases', 'of', 'papers', 'published', 'between', '_year_', 'and', '_year_', 'was', 'conducted', 'using', 'the', 'following', 'medical', 'subject', 'headings', 'or', 'key', 'words', 'insomnia', 'primary', 'insomnia', 'psychophysiological', 'insomnia', 'sleep', 'maintenance', 'disorders', 'sleep', 'initiation', 'disorders', 'non', 'pharmacological', 'treatment', 'and', 'cognitive', 'behavioural', 'therapy']]
Studies were selected for inclusion if they fit the following criteria design was a (randomized) clinical trial (RCT); all patients had suffered a whiplash-injury; the type of intervention was a conservative one; pain, global perceived effect, or participation in daily activities was used as one of the outcome measures; and the publication was written in English, French, German or Dutch. 	 [['studies', 'were', 'selected', 'for', 'inclusion', 'if', 'they', 'fit', 'the', 'following', 'criteria', 'design', 'was', 'a', 'randomized', 'clinical', 'trial', 'rct', 'all', 'patients', 'had', 'suffered', 'a', '_disease_', 'the', 'type', 'of', 'intervention', 'was', 'a', 'conservative', '_num_', 'pain', 'global', 'perceived', 'effect', 'or', 'participation', 'in', 'daily', 'activities', 'was', 'used', 'as', '_num_', 'of', 'the', 'outcome', 'measures', 'and', 'the', 'publication', 'was', 'written', 'in', 'english', 'french', 'german', 'or', 'dutch']]
The experimental group will receive CPM + physiotherapy for 17 consecutive days after surgery, whereas the usual care group will receive the same treatment during the in-hospital phase  ie about four days), followed by physical therapy alone (usual care) in the first two weeks after hospital discharge.From 18 days to three months after discharge, both groups will receive standardised PT. 	 [['the', 'experimental', 'group', 'will', 'receive', 'cpm', 'physiotherapy', 'for', '_num_', 'consecutive', 'days', 'after', 'surgery', 'whereas', 'the', 'usual', 'care', 'group', 'will', 'receive', 'the', 'same', 'treatment', 'during', 'the', '_disease_', 'phase', 'ie', 'about', '_num_', 'days', 'followed', 'by', 'physical', 'therapy', 'alone', 'usual', 'care', 'in', 'the', '_num_', '_num_', 'weeks', 'after', 'hospital', 'discharge', 'from', '_num_', 'days', 'to', '_num_', 'months', 'after', 'discharge', 'both', 'groups', 'will', 'receive', 'standardised', 'pt']]
We searched MEDLINE (1966 to February 2004); the Cochrane Central Register of Controlled Trials (CENTRAL), (The Cochrane Library, Issue 2, 2004); CINAHL (1982 to February 2004); PsycINFO (1972 to February 2004); ERIC (1982 to February 2004); Sociological Abstracts (1963 to February 2004); Social Work Abstracts (1977 to February 2004); and AMI (Australasian Medical Index) (1966 to February 2004). 	 [['we', 'searched', 'medline', '_year_', 'to', 'february', '_year_', 'the', 'cochrane', 'central', 'register', 'of', 'controlled', 'trials', 'central', 'the', 'cochrane', 'library', 'issue', '_num_', '_year_', 'cinahl', '_year_', 'to', 'february', '_year_', 'psycinfo', '_year_', 'to', 'february', '_year_', 'eric', '_year_', 'to', 'february', '_year_', 'sociological', 'abstracts', '_year_', 'to', 'february', '_year_', 'social', 'work', 'abstracts', '_year_', 'to', 'february', '_year_', 'and', '_disease_', 'australasian', 'medical', 'index', '_year_', 'to', 'february', '_year_']]
Outcome measures included 1) a visual analog scale to assess the intensity of spontaneous low back and radicular pain, 2) a straight leg-raising maneuver to assess the degree of leg elevation in relation to evoked sciatic pain, 3) postoperative time to comfortable walking, 4) duration of postoperative hospitalization, 5) required amount of postoperative analgesics, and 6) postoperative work time loss. 	 [['outcome', 'measures', 'included', '_num_', 'a', 'visual', 'analog', 'scale', 'to', 'assess', 'the', 'intensity', 'of', 'spontaneous', 'low', 'back', 'and', '_disease_', 'pain', '_num_', 'a', 'straight', 'leg', 'raising', 'maneuver', 'to', 'assess', 'the', 'degree', 'of', 'leg', 'elevation', 'in', 'relation', 'to', 'evoked', 'sciatic', 'pain', '_num_', 'postoperative', 'time', 'to', 'comfortable', 'walking', '_num_', 'duration', 'of', 'postoperative', 'hospitalization', '_num_', 'required', 'amount', 'of', 'postoperative', 'analgesics', 'and', '_num_', 'postoperative', 'work', 'time', 'loss']]
To define the population of cells injured by paclitaxel, we examined the expression of activating transcription factor-3 (ATF3), a marker of cell injury; to define the hypertrophy of satellite cells, we quantified the expression of the intermediate filament protein glial fibrillary acidic protein (GFAP); and to define the activation of macrophages, we examined the expression of the lysosomal protein CD68. 	 [['to', 'define', 'the', 'population', 'of', 'cells', 'injured', 'by', '_chemical_', 'we', 'examined', 'the', 'expression', 'of', 'activating', 'transcription', '_abbrev_', '_gene_', 'a', 'marker', 'of', 'cell', 'injury', 'to', 'define', 'the', 'hypertrophy', 'of', 'satellite', 'cells', 'we', 'quantified', 'the', 'expression', 'of', 'the', 'intermediate', 'filament', 'protein', 'glial', 'fibrillary', 'acidic', 'protein', '_gene_', 'and', 'to', 'define', 'the', 'activation', 'of', 'macrophages', 'we', 'examined', 'the', 'expression', 'of', 'the', 'lysosomal', 'protein', '_gene_']]
The comparison group had to be placebo or no treatment or the same co intervention (ACTH or steroids) The main outcome criteria were  progression of disability (defined as an increase of 0.5 point in Kurtzke Extended Disability Status Scale (EDSS) for patients with baseline EDSS > or = 6 and 1 for EDSS &lt; or = 5.5), differences of disability between treatment-control groups and the number of patients with side effects. 	 [['the', 'comparison', 'group', 'had', 'to', 'be', 'placebo', 'or', 'no', 'treatment', 'or', 'the', 'same', 'co', 'intervention', 'acth', 'or', 'steroids', 'the', 'main', 'outcome', 'criteria', 'were', 'progression', 'of', 'disability', 'defined', 'as', 'an', 'increase', 'of', '_num_', 'point', 'in', 'kurtzke', 'extended', 'disability', 'status', 'scale', 'edss', 'for', 'patients', 'with', 'baseline', 'edss', 'or', '_ineq_', '_num_', 'and', '_num_', 'for', 'edss', '_ineq_', 'or', '_ineq_', '_num_', 'differences', 'of', 'disability', 'between', 'treatment', 'control', 'groups', 'and', 'the', 'number', 'of', 'patients', 'with', 'side', 'effects']]
A literature search was conducted to identify randomised controlled trials of IBS treatments 45 studies were identified that described randomised controlled trials and of these, six fulfilled all three criteria used to assess the quality of randomised controlled trials, as described by Jadad and colleagues.(1) These criteria are adequate description of randomisation, double blinding, and description of withdrawals and dropouts. 	 [['a', 'literature', 'search', 'was', 'conducted', 'to', 'identify', 'randomised', 'controlled', 'trials', 'of', 'ibs', 'treatments', '_num_', 'studies', 'were', 'identified', 'that', 'described', 'randomised', 'controlled', 'trials', 'and', 'of', 'these', '_num_', 'fulfilled', 'all', '_num_', 'criteria', 'used', 'to', 'assess', 'the', 'quality', 'of', 'randomised', 'controlled', 'trials', 'as', 'described', 'by', 'jadad', 'and', 'colleagues', '_num_', 'these', 'criteria', 'are', 'adequate', 'description', 'of', 'randomisation', 'double', 'blinding', 'and', 'description', 'of', 'withdrawals', 'and', 'dropouts']]
Studies for inclusion in the review were identified using the Cochrane Movement Disorders Group trials register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, by handsearching the Movement Disorders Journal and abstracts of international congresses on movement disorders and botulinum toxin, by communication with other researchers in the field, by searching reference lists of papers found using the above search strategies, and by contact with authors and drug manufacturer. 	 [['studies', 'for', 'inclusion', 'in', 'the', 'review', 'were', 'identified', 'using', 'the', 'cochrane', 'movement', 'disorders', 'group', 'trials', 'register', 'the', 'cochrane', 'central', 'register', 'of', 'controlled', 'trials', 'central', 'medline', 'embase', 'by', 'handsearching', 'the', 'movement', 'disorders', 'journal', 'and', 'abstracts', 'of', 'international', 'congresses', 'on', 'movement', 'disorders', 'and', 'botulinum', 'toxin', 'by', 'communication', 'with', 'other', 'researchers', 'in', 'the', 'field', 'by', 'searching', 'reference', 'lists', 'of', 'papers', 'found', 'using', 'the', 'above', 'search', 'strategies', 'and', 'by', 'contact', 'with', 'authors', 'and', 'drug', 'manufacturer']]
Outcome measures included (1) visual analog scale (VAS) to assess the intensity of spontaneous low back and radicular pain, (2) straight-leg-raising maneuver to assess the degrees of leg elevation in relation to evoked-sciatic pain, (3) postoperative time to comfortable ambulation, (4) duration of postoperative hospitalization, (5) required amount of postoperative analgesics, (6) postoperative work time loss, and (7) follow-up lumbar magnetic resonance imaging or segmental computed tomography with contrast medium for quantitative evaluation of postoperative epidural fibrosis. 	 [['outcome', 'measures', 'included', '_num_', 'visual', 'analog', 'scale', 'vas', 'to', 'assess', 'the', 'intensity', 'of', 'spontaneous', 'low', 'back', 'and', '_disease_', 'pain', '_num_', 'straight', 'leg', 'raising', 'maneuver', 'to', 'assess', 'the', 'degrees', 'of', 'leg', 'elevation', 'in', 'relation', 'to', 'evoked', 'sciatic', 'pain', '_num_', 'postoperative', 'time', 'to', 'comfortable', 'ambulation', '_num_', 'duration', 'of', 'postoperative', 'hospitalization', '_num_', 'required', 'amount', 'of', 'postoperative', 'analgesics', '_num_', 'postoperative', 'work', 'time', 'loss', 'and', '_num_', 'follow', 'up', 'lumbar', 'magnetic', 'resonance', 'imaging', 'or', 'segmental', 'computed', 'tomography', 'with', 'contrast', 'medium', 'for', 'quantitative', 'evaluation', 'of', 'postoperative', 'epidural', 'fibrosis']]

PIBOSO outcome:

We conclude that because access variables such as lack of employment and knowledge about where to obtain care were more closely associated with clinically significant delay than was severity of illness, these results raise concerns about the equity of acc 	 [['we', 'conclude', 'that', 'because', 'access', 'variables', 'such', 'as', 'lack', 'of', 'employment', 'and', 'knowledge', 'about', 'where', 'to', 'obtain', 'care', 'were', 'more', 'closely', 'associated', 'with', 'clinically', 'significant', 'delay', 'than', 'was', 'severity', 'of', 'illness', 'these', 'results', 'raise', 'concerns', 'about', 'the', 'equity', 'of', 'acc']]
These results, showing alleviation of x-irradiation-related deficits in short-term memory by D-amphetamine injections, along with our earlier and present results, showing substantial deficits after x-irradiation alone, encourage the hypothesis that hippoc 	 [['these', 'results', 'showing', 'alleviation', 'of', 'x', 'irradiation', 'related', 'deficits', 'in', 'short', 'term', 'memory', 'by', '_gene_', 'injections', 'along', 'with', 'our', 'earlier', 'and', 'present', 'results', 'showing', 'substantial', 'deficits', 'after', 'x', 'irradiation', 'alone', 'encourage', 'the', 'hypothesis', 'that', 'hippoc']]
Overall, the results showed a systematic decrease in mean neuropsychological test performance as a function of increasing GOS severity, as well as an increased prevalence of symptoms of depression and lower ratings on measures assessing employability and  	 [['overall', 'the', 'results', 'showed', 'a', 'systematic', 'decrease', 'in', 'mean', 'neuropsychological', 'test', 'performance', 'as', 'a', 'function', 'of', 'increasing', 'gos', 'severity', 'as', 'well', 'as', 'an', 'increased', 'prevalence', 'of', 'symptoms', 'of', 'depression', 'and', 'lower', 'ratings', 'on', 'measures', 'assessing', 'employability', 'and']]
In conclusion, the MMCBT do not seem to be effective in reducing sick-leave compared to no treatment, but the MMCBT program is superior in decreasing pain intensity, enhancing self-reported behavioural changes in personal life and improving pain coping ab 	 [['in', 'conclusion', 'the', 'mmcbt', 'do', 'not', 'seem', 'to', 'be', 'effective', 'in', 'reducing', '_disease_', 'compared', 'to', 'no', 'treatment', 'but', 'the', 'mmcbt', 'program', 'is', 'superior', 'in', 'decreasing', 'pain', 'intensity', 'enhancing', 'self', 'reported', 'behavioural', 'changes', 'in', 'personal', 'life', 'and', 'improving', 'pain', 'coping', 'ab']]
When compared to patients with traumatic SCI, patients with SS were significantly (t-test, p &lt; .01) older (mean age 68 versus 39 years), more frequently retired/unemployed (89 percent versus 43 percent), more often married (57 percent versus 36 percent 	 [['when', 'compared', 'to', 'patients', 'with', 'traumatic', 'sci', 'patients', 'with', 'ss', 'were', 'significantly', 't', 'test', 'p', '_ineq_', '_num_', 'older', 'mean', 'age', '_num_', 'vs', '_num_', 'years', 'more', 'frequently', 'retired', 'unemployed', '_num_', 'percent', 'vs', '_num_', 'percent', 'more', 'often', 'married', '_num_', 'percent', 'vs', '_num_', 'percent']]
This study suggests that individuals with weakness secondary to SS represent a significant proportion of individuals with SCI, make significant functional gains following inpatient rehabilitation and can achieve functional outcomes similar to those of tra 	 [['this', 'study', 'suggests', 'that', 'individuals', 'with', 'weakness', 'secondary', 'to', 'ss', 'represent', 'a', 'significant', 'proportion', 'of', 'individuals', 'with', 'sci', 'make', 'significant', 'functional', 'gains', 'following', 'inpatient', 'rehabilitation', 'and', 'can', 'achieve', 'functional', 'outcomes', 'similar', 'to', 'those', 'of', '_gene_']]
This allodynia was relieved by clonidine (50% block of allodynia at 20+/-1.2 microg and neostigmine (50% block of allodynia at 2+/-0.1 microg, and they interacted synergistically to block allodynia. Neither chemical nor surgical sympathectomy altered allo 	 [['this', '_disease_', 'was', 'relieved', 'by', 'clonidine', '_num_', '_percent_', 'block', 'of', '_disease_', 'at', '20+', '', '_num_', '_num_', 'microg', 'and', 'neostigmine', '_num_', '_percent_', 'block', 'of', '_disease_', 'at', '2+', '', '_num_', '_num_', 'microg', 'and', 'they', 'interacted', 'synergistically', 'to', 'block', '_disease_', 'neither', 'chemical', 'nor', 'surgical', 'sympathectomy', 'altered', 'allo']]
The results suggest that an unvarying home-based exercise program may support general agility but does not yield enough force to improve muscle strength and postural stability in healthy, nondisabled, postmenopausal women who start exercising at the age o 	 [['the', 'results', 'suggest', 'that', 'an', 'unvarying', 'home', 'based', 'exercise', 'program', 'may', 'support', 'general', 'agility', 'but', 'does', 'not', 'yield', 'enough', 'force', 'to', 'improve', 'muscle', 'strength', 'and', 'postural', 'stability', 'in', 'healthy', 'nondisabled', 'postmenopausal', 'women', 'who', 'start', 'exercising', 'at', 'the', 'age', 'o']]
However, both patients in group II (73%) and group III (78%) had significantly higher overall response rates when compared to those observed in group I (59%) (I vs II, p=0.025; I vs III, p=0.0019), and with no difference between groups II and III (p=0.39) 	 [['however', 'both', 'patients', 'in', 'group', 'ii', '_num_', '_percent_', 'and', 'group', 'iii', '_num_', '_percent_', 'had', 'significantly', 'higher', 'overall', 'response', 'rates', 'when', 'compared', 'to', 'those', 'observed', 'in', 'group', 'i', '_num_', '_percent_', 'i', 'vs', 'ii', '_p_val_', 'i', 'vs', 'iii', '_p_val_', 'and', 'with', 'no', 'difference', 'between', 'groups', 'ii', 'and', 'iii', '_p_val_']]
Results of this study seem to confirm that 8 Gy could be considered as probably &quot;lowest&quot; optimal single fraction RT in the treatment of painful bone metastasis, although single fraction RT of 4 Gy should not be easily discarded due to its applic 	 [['results', 'of', 'this', 'study', 'seem', 'to', 'confirm', 'that', '_num_', 'gy', 'could', 'be', 'considered', 'as', 'probably', 'quot', 'lowest', 'quot', 'optimal', 'single', 'fraction', 'rt', 'in', 'the', 'treatment', 'of', 'painful', 'bone', 'metastasis', 'although', 'single', 'fraction', 'rt', 'of', '_num_', 'gy', 'should', 'not', 'be', 'easily', 'discarded', 'due', 'to', 'its', 'applic']]
Preliminary results from focus groups and in-depth interviews indicate that women are concerned about the safety of the reduced number of visits during pregnancy (four for low-risk women) inherent in the experimental regimen, prefer to receive care from s 	 [['preliminary', 'results', 'from', 'focus', 'groups', 'and', 'in', 'depth', 'interviews', 'indicate', 'that', 'women', 'are', 'concerned', 'about', 'the', 'safety', 'of', 'the', 'reduced', 'number', 'of', 'visits', 'during', 'pregnancy', '_num_', 'for', '_disease_', 'women', 'inherent', 'in', 'the', 'experimental', 'regimen', 'prefer', 'to', 'receive', 'care', 'from', 's']]
Such qualitative information, together with data obtained from questionnaires, will highlight areas that must be addressed if the new prenatal care model is to be introduced on a routine basis.americasarab countriesargentinaasiabehaviorcaribbeancross sect 	 [['such', 'qualitative', 'information', 'together', 'with', 'data', 'obtained', 'from', 'questionnaires', 'will', 'highlight', 'areas', 'that', 'must', 'be', 'addressed', 'if', 'the', 'new', 'prenatal', 'care', 'model', 'is', 'to', 'be', 'introduced', 'on', 'a', 'routine', 'basis', 'americasarab', 'countriesargentinaasiabehaviorcaribbeancross', 'sect']]
However, after long-term treatment with the tricyclic antidepressant imipramine, the selective 5-HT reuptake inhibitor paroxetine, the reversible monoamine oxidase-A inhibitor befloxatone, the alpha2-adrenergic antagonist mirtazapine, or the 5-HT1A recept 	 [['however', 'after', 'long', 'term', 'treatment', 'with', 'the', 'tricyclic', 'antidepressant', 'imipramine', 'the', 'selective', '_chemical_', 'reuptake', 'inhibitor', '_chemical_', 'the', 'reversible', 'monoamine', 'oxidase', 'a', 'inhibitor', '_chemical_', 'the', '_chemical_', 'antagonist', '_chemical_', 'or', 'the', '_gene_', 'recept']]
Such a disinhibition was absent in rats treated with the nonantidepressant drug chlorpromazine, in rats receiving only one ECS, or in rats receiving multiple ECSs in combination with an intrahippocampal pertussis toxin treatment to inactivate Gi/o-coupled 	 [['such', 'a', '_disease_', 'was', 'absent', 'in', 'rats', 'treated', 'with', 'the', 'nonantidepressant', 'drug', 'chlorpromazine', 'in', 'rats', 'receiving', 'only', '_num_', 'ecs', 'or', 'in', 'rats', 'receiving', 'multiple', 'ecss', 'in', 'combination', 'with', 'an', 'intrahippocampal', 'pertussis', 'toxin', 'treatment', 'to', 'inactivate', 'gi', 'o', 'coupled']]
These findings provide evidence of increased activity of STN neurotransmitter systems in PD and demonstrate for the first time in any species that basal ganglia nitric oxide systems can be selectively regulated in response to changes in dopaminergic input 	 [['these', 'findings', 'provide', 'evidence', 'of', 'increased', 'activity', 'of', '_gene_', 'neurotransmitter', 'systems', 'in', 'pd', 'and', 'demonstrate', 'for', 'the', '_num_', 'time', 'in', 'any', 'species', 'that', 'basal', 'ganglia', 'nitric', 'oxide', 'systems', 'can', 'be', 'selectively', 'regulated', 'in', 'response', 'to', 'changes', 'in', '_chemical_', 'input']]
From the analysis of the published studies it appears that bisphosphonates and, in particular, intravenous Disodium Pamidronate, are not only able to slow down the progression of the disease and to reduce the onset of skeletal complications but also have  	 [['from', 'the', 'analysis', 'of', 'the', 'published', 'studies', 'it', 'appears', 'that', '_disease_', 'and', 'in', 'particular', 'intravenous', '_chemical_', '_chemical_', 'are', 'not', 'only', 'able', 'to', 'slow', 'down', 'the', 'progression', 'of', 'the', 'disease', 'and', 'to', 'reduce', 'the', 'onset', 'of', 'skeletal', 'complications', 'but', 'also', 'have']]
It still remains to be seen if the newer and more potent bisphosphonates such as Ibandronate and Zoledronate can be administered differently from the intravenous route such as by mouth or by patch which are readily accepted by the patient and, moreover, i 	 [['it', 'still', 'remains', 'to', 'be', 'seen', 'if', 'the', 'newer', 'and', 'more', 'potent', '_disease_', 'such', 'as', '_chemical_', 'and', '_chemical_', 'can', 'be', 'administered', 'differently', 'from', 'the', 'intravenous', 'route', 'such', 'as', 'by', 'mouth', 'or', 'by', 'patch', 'which', 'are', 'readily', 'accepted', 'by', 'the', 'patient', 'and', 'moreover', 'i']]
The clinical pregnancy rate in group A was 12.9% compared with 24.6% in group B. CONCLUSION(S): The administration of progesterone before oocyte retrieval is associated with a lower pregnancy rate than the administration of progesterone after oocyte retri 	 [['the', 'clinical', 'pregnancy', 'rate', 'in', 'group', 'a', 'was', '_num_', '_percent_', 'compared', 'with', '_num_', '_percent_', 'in', 'group', 'b', 'conclusion', 's', 'the', 'administration', 'of', 'progesterone', 'before', 'oocyte', 'retrieval', 'is', 'associated', 'with', 'a', 'lower', 'pregnancy', 'rate', 'than', 'the', 'administration', 'of', 'progesterone', 'after', 'oocyte', 'retri']]
Raft phospholipids were analyzed by mass spectrometry.RESULTS.  Our results showed that EPA treatment could alter lipid composition resulting in a considerable increase of unsaturated fatty acyl chains in lipid rafts from EPA-treated T cells compared with  	 [['raft', 'phospholipids', 'were', 'analyzed', 'by', 'mass', 'spectrometry', 'results', 'our', 'results', 'showed', 'that', 'epa', 'treatment', 'could', 'alter', 'lipid', 'composition', 'resulting', 'in', 'a', 'considerable', 'increase', 'of', 'unsaturated', 'fatty', 'acyl', 'chains', 'in', 'lipid', 'rafts', 'from', 'epa', 'treated', 't', 'cells', 'compared', 'with']]
EPA presented an inhibiting effect on Jurkat T cells proliferation and inhibited IL-2Ralpha expression on the surface of T cells.CONCLUSIONS.  Our data provided evidence for an important modification in lipid composition of membrane lipid rafts and T cell  	 [['epa', 'presented', 'an', 'inhibiting', 'effect', 'on', 'jurkat', 't', 'cells', 'proliferation', 'and', 'inhibited', '_abbrev_', 'expression', 'on', 'the', 'surface', 'of', 't', 'cells', 'conclusions', 'our', 'data', 'provided', 'evidence', 'for', 'an', 'important', 'modification', 'in', 'lipid', 'composition', 'of', 'membrane', 'lipid', 'rafts', 'and', 't', 'cell']]

---------------------------------------------------------------- 
Word vectors for subsets of CIViC and Abstracts 
----------------------------------------------------------------

IC50 for cell number in response to 17-AAG was 33.4 nM, in contrast to IC50 for EML4-ALK wild type, which was 98.9 nM, suggesting sensitization of this variant to HSP90 inhibition. 
 [['_abbrev_', 'for', 'cell', 'number', 'in', 'response', 'to', '_num_', '_gene_', 'was', '_num_', '_unit_', 'in', 'contrast', 'to', '_abbrev_', 'for', '_abbrev_', '_gene_', 'wild', 'type', 'which', 'was', '_num_', '_unit_', 'suggesting', 'sensitization', 'of', 'this', 'variant', 'to', '_gene_', 'inhibition']] 

All 4 family members carried cerebellar hemangioblastomas, 2 of 4 carried angiomas and one carried renal cell carcinoma. 
 [['all', '_num_', 'family', 'members', 'carried', 'cerebellar', '_disease_', '_num_', 'of', '_num_', 'carried', 'angiomas', 'and', '_num_', 'carried', 'renal', 'cell', 'carcinoma']] 

This study finds evidence for SOX10 loss (N=2) and/or activation of TGF-β signalling (N=2) in 4 of the 6 EGFR-positive drug-resistant melanoma patient samples. 
 [['this', 'study', 'finds', 'evidence', 'for', '_gene_', 'loss', '_gene_', 'and', 'or', 'activation', 'of', 'tgf', 'β', 'signalling', '_gene_', 'in', '_num_', 'of', 'the', '_num_', '_gene_', 'positive', '_disease_', 'melanoma', 'patient', 'samples']] 

243 primary PCa, 37 metastatic PCa, and  20  castration-resistant  PCa  (CRPC) specimens underwent IHC and microarray analysis. 
 [['_num_', 'primary', '_disease_', '_num_', 'metastatic', '_disease_', 'and', '_num_', 'castration', 'resistant', '_disease_', 'crpc', 'specimens', 'underwent', 'ihc', 'and', 'microarray', 'analysis']] 

1 case was verified by RT-PCR to be a SLC34A2-ROS1 fusion, but this case was also positive for BRAF V600E. 
 [['_num_', 'case', 'was', 'verified', 'by', 'rt', 'pcr', 'to', 'be', 'a', '_abbrev_', 'fusion', 'but', 'this', 'case', 'was', 'also', 'positive', 'for', '_gene_', '_abbrev_']] 

ACMG evidence codes: 'PP1' based on segregation results, 'PP4' the patients phenotypes are highly specific for a disease with single genetic etiology. 
 [['acmg', 'evidence', 'codes', "'pp1", 'based', 'on', 'segregation', 'results', "'pp4", 'the', 'patients', 'phenotypes', 'are', 'highly', 'specific', 'for', 'a', 'disease', 'with', 'single', 'genetic', 'etiology']] 

This mutation was found in a VHL type 1 family of 5 individuals. 
 [['this', 'mutation', 'was', 'found', 'in', 'a', '_gene_', 'type', '_num_', 'family', 'of', '_num_', 'individuals']] 

This phenomenon was observed in patients treated in the pre-TKI era as well as those treated with imatinib when compared to wild type patients undergoing similar treatment. 
 [['this', 'phenomenon', 'was', 'observed', 'in', 'patients', 'treated', 'in', 'the', '_gene_', 'tki', 'era', 'as', 'well', 'as', 'those', 'treated', 'with', '_chemical_', 'when', 'compared', 'to', 'wild', 'type', 'patients', 'undergoing', 'similar', 'treatment']] 

Although from 2004, this study remains cited in 2016 literature when discussing the unclear efficacy of trastuzumab in wild type HER2 overexpressing NSCLC. 
 [['although', 'from', '_year_', 'this', 'study', 'remains', 'cited', 'in', '_year_', 'literature', 'when', 'discussing', 'the', 'unclear', 'efficacy', 'of', '_chemical_', 'in', 'wild', 'type', '_gene_', 'overexpressing', '_disease_']] 

In a study of 78 patients with gastrointestinal stromal tumors treated with sunitinib, patients with Kit exon 9 mutations or wildtype (lacking KIT or PDGFRA mutations) showed increased progression free survival and overall survival compared to patients with Kit exon 11 mutations. 
 [['in', 'a', 'study', 'of', '_num_', 'patients', 'with', 'gastrointestinal', 'stromal', 'tumors', 'treated', 'with', '_chemical_', 'patients', 'with', 'kit', 'exon', '_num_', 'mutations', 'or', 'wildtype', 'lacking', 'kit', 'or', '_gene_', 'mutations', 'showed', 'increased', 'progression', 'free', 'survival', 'and', 'overall', 'survival', 'compared', 'to', 'patients', 'with', 'kit', 'exon', '_num_', 'mutations']] 

Both had retinal angiomas and cerebellar hemangioblastomas. 
 [['both', 'had', 'retinal', 'angiomas', 'and', 'cerebellar', '_disease_']] 

The patient was treated with crizotinib and experienced a complete normalization of tumor metabolic activity for more than 19 months. 
 [['the', 'patient', 'was', 'treated', 'with', '_chemical_', 'and', 'experienced', 'a', 'complete', 'normalization', 'of', 'tumor', 'metabolic', 'activity', 'for', 'more', 'than', '_num_', 'months']] 

Meta-analysis of 25 studies involving 13,629 women with tamoxifen treated breast cancer. 
 [['_disease_', 'analysis', 'of', '_num_', 'studies', 'involving', '_num_', 'women', 'with', 'tamoxifen', 'treated', 'breast', 'cancer']] 

In Western blots, ablation of pALK with brigatinib treatment above 100 nM was seen in Ba/F3 cells expressing NPM-ALK wildtype, but remained apparent at 1000 nM brigatinib in NPM-ALK G1202R cells, despite dose-dependent reduction. 
 [['in', 'western', 'blots', 'ablation', 'of', 'palk', 'with', '_chemical_', 'treatment', 'above', '_num_', '_unit_', 'was', 'seen', 'in', 'ba', '_abbrev_', 'cells', 'expressing', '_gene_', '_gene_', 'wildtype', 'but', 'remained', 'apparent', 'at', '_num_', '_unit_', '_chemical_', 'in', '_gene_', '_gene_', '_abbrev_', 'cells', 'despite', '_disease_', 'reduction']] 

One VHL type 1 family of 2 affected individuals had one patient with retinal angiomas, 2 with hemangioblastomas of the central nervous system, one with renal cell carcinoma, one with pancreatic cysts, and  one with cystadenomas of the epididymis (family VHL 32). 
 [['_num_', '_gene_', 'type', '_num_', 'family', 'of', '_num_', 'affected', 'individuals', 'had', '_num_', 'patient', 'with', 'retinal', 'angiomas', '_num_', 'with', '_disease_', 'of', 'the', 'central', 'nervous', 'system', '_num_', 'with', 'renal', 'cell', 'carcinoma', '_num_', 'with', 'pancreatic', 'cysts', 'and', '_num_', 'with', '_disease_', 'of', 'the', 'epididymis', 'family', '_gene_', '_num_']] 

The prevalence of various mutations post-treatment was analyzed. 
 [['the', 'prevalence', 'of', 'various', 'mutations', 'post', 'treatment', 'was', 'analyzed']] 

81 patients were enrolled in the trial and treated with dovitinib. 
 [['_num_', 'patients', 'were', 'enrolled', 'in', 'the', 'trial', 'and', 'treated', 'with', '_chemical_']] 

The stable disease patient had an R1275L mutation in ALK. 
 [['the', 'stable', 'disease', 'patient', 'had', 'an', '_mutation_', 'mutation', 'in', '_gene_']] 

The patient also harbored an MLH1 c.453+1G > A mutation. 
 [['the', 'patient', 'also', 'harbored', 'an', '_gene_', 'c', '453+1g', 'a', 'mutation']] 

Whole-exome sequencing of the pre-treatment tumor revealed a MAPK1 E322K mutation (allelic fraction 0.13). 
 [['whole', 'exome', 'sequencing', 'of', 'the', '_gene_', 'treatment', 'tumor', 'revealed', 'a', '_gene_', '_abbrev_', 'mutation', 'allelic', 'fraction', '_num_']] 

Thus, EGF is a potential predictive biomarker of poor cetuximab response and a possible treatment target. 
 [['thus', '_gene_', 'is', 'a', 'potential', 'predictive', '_chemical_', 'of', 'poor', '_chemical_', 'response', 'and', 'a', 'possible', 'treatment', 'target']] 

BACKGROUND. 
 [['background']] 

Primary reason for exclusion was ineligibility. 
 [['primary', 'reason', 'for', 'exclusion', 'was', 'ineligibility']] 

Analysis of this patient's relapse genome revealed an unexpected, actionable therapeutic target that led to a specific therapy associated with a rapid clinical response. 
 [['analysis', 'of', 'this', 'patient', "'s", 'relapse', 'genome', 'revealed', 'an', 'unexpected', 'actionable', 'therapeutic', 'target', 'that', 'led', 'to', 'a', 'specific', 'therapy', 'associated', 'with', 'a', 'rapid', 'clinical', 'response']] 

Understanding the effector pathways downstream of these oncoproteins is important to identify opportunities for targeted therapy. 
 [['understanding', 'the', 'effector', 'pathways', 'downstream', 'of', 'these', 'oncoproteins', 'is', 'important', 'to', 'identify', 'opportunities', 'for', 'targeted', 'therapy']] 

Paired tumor biopsies were mandated at the MTD for biomarker studies. 
 [['paired', 'tumor', 'biopsies', 'were', 'mandated', 'at', 'the', '_gene_', 'for', '_chemical_', 'studies']] 

The sustained clinical activity of the BRAF inhibitor vemurafenib (PLX4032/RG7204) in patients with BRAF(V600) mutant melanoma is limited primarily by the development of acquired resistance leading to tumor progression. 
 [['the', 'sustained', 'clinical', 'activity', 'of', 'the', '_gene_', 'inhibitor', '_chemical_', '_abbrev_', '_abbrev_', 'in', 'patients', 'with', '_gene_', '_abbrev_', 'mutant', 'melanoma', 'is', 'limited', 'primarily', 'by', 'the', 'development', 'of', 'acquired', 'resistance', 'leading', 'to', 'tumor', 'progression']] 

This polymorphism, a missense variant in the gene SH2B3, is also associated with haematological and autoimmune disorders, suggesting that it influences cancer risk through the immune response. 
 [['this', 'polymorphism', 'a', 'missense', 'variant', 'in', 'the', 'gene', '_abbrev_', 'is', 'also', 'associated', 'with', 'haematological', 'and', 'autoimmune', 'disorders', 'suggesting', 'that', 'it', 'influences', 'cancer', 'risk', 'through', 'the', 'immune', 'response']] 

Patients homozygous for the reference alleles (GG) of PPP1R15A rs557806 exhibited greater disease control rate and a tendency toward greater objective response rate (ORR) than those with homozygous or heterozygous substitution alleles (GC and CC; P = 0.027 and 0.073, respectively). 
 [['patients', 'homozygous', 'for', 'the', 'reference', 'alleles', 'gg', 'of', '_gene_', '_mutation_', 'exhibited', 'greater', 'disease', 'control', 'rate', 'and', 'a', 'tendency', 'toward', 'greater', 'objective', 'response', 'rate', 'orr', 'than', 'those', 'with', 'homozygous', 'or', 'heterozygous', 'substitution', 'alleles', 'gc', 'and', 'cc', 'p', '_ineq_', '_num_', 'and', '_num_', 'respectively']] 

Our findings highlight the importance of studying drug resistance mechanisms in order to develop effective clinical treatments for patients with ALK-translocated cancers. 
 [['our', 'findings', 'highlight', 'the', 'importance', 'of', 'studying', 'drug', 'resistance', 'mechanisms', 'in', 'order', 'to', 'develop', 'effective', 'clinical', 'treatments', 'for', 'patients', 'with', '_gene_', 'translocated', 'cancers']] 

These results suggest that midostaurin has hematologic activity in both patients with FLT3-mutant and wild type. 
 [['these', 'results', 'suggest', 'that', '_chemical_', 'has', 'hematologic', 'activity', 'in', 'both', 'patients', 'with', '_gene_', 'mutant', 'and', 'wild', 'type']] 

CLINICAL TRIAL REGISTRATION NUMBERS: NCT00503997, NCT00425750, NCT00003809. 
 [['clinical', 'trial', 'registration', 'numbers', '_abbrev_', '_abbrev_', '_abbrev_']] 

Primary cross-resistance was confirmed in an independent set of 23 BRAF-mutant short-term melanoma cell cultures. 
 [['primary', '_disease_', 'was', 'confirmed', 'in', 'an', 'independent', 'set', 'of', '_num_', '_gene_', 'mutant', 'short', 'term', 'melanoma', 'cell', 'cultures']] 

A total of 121 patients were randomly assigned. 
 [['a', 'total', 'of', '_num_', 'patients', 'were', 'randomly', 'assigned']] 

Our work is the first to address the molecular status of FGFR3 in Jordanian patients with bladder cancer, and provides further support for FGFR3 as a key player in the initiation of bladder tumors. 
 [['our', 'work', 'is', 'the', '_num_', 'to', 'address', 'the', 'molecular', 'status', 'of', '_gene_', 'in', 'jordanian', 'patients', 'with', 'bladder', 'cancer', 'and', 'provides', 'further', 'support', 'for', '_gene_', 'as', 'a', 'key', 'player', 'in', 'the', 'initiation', 'of', 'bladder', 'tumors']] 

Response was related to FGFR3 and/or FGFR1 expression levels. 
 [['response', 'was', 'related', 'to', '_gene_', 'and', 'or', '_gene_', 'expression', 'levels']] 

METHODS. 
 [['methods']] 

PATIENTS AND METHODS. 
 [['patients', 'and', 'methods']] 

An EGFR CA simple sequence repeat in intron 1 (CA-SSR1) polymorphism was evaluated in blood. 
 [['an', '_gene_', 'ca', 'simple', 'sequence', 'repeat', 'in', 'intron', '_num_', '_abbrev_', 'polymorphism', 'was', 'evaluated', 'in', 'blood']] 

The endogenous HPV status or the expression of HPV oncogenes had no significant impact on cetuximab-mediated suppression of EGFR signaling and proliferation in vitro. 
 [['the', 'endogenous', 'hpv', 'status', 'or', 'the', 'expression', 'of', 'hpv', 'oncogenes', 'had', 'no', 'significant', 'impact', 'on', '_chemical_', 'mediated', 'suppression', 'of', '_gene_', 'signaling', 'and', 'proliferation', 'in', 'vitro']] 


Process finished with exit code 0
